1   **Induction of antiviral Interferon-Stimulated Genes (ISGs) by neuronal STING promotes**
2   **the resolution of pain.**
3
4

5   Manon Defaye[1,2,3$], Amyaouch Bradaia[1,2,3$], Nasser S. Abdullah[1,2,3], Francina Agosti[1,2,3], Mircea
6   Iftinca[1,2,3], Vanessa Soubeyre[6], Kristofer Svendsen[1,2,3,4], Gurveer Gill[1,2], Mélissa Cuménal[1,2,3],
7   Nadine Gheziel[5], Jérémy Martin[5], Lilian Basso[5], Emmanuel Bourinet[6], Isaac M. Chiu[7], Christophe
8   Altier[1,2,3,4*]
9

[1]Department of Physiology and Pharmacology, Cumming School of Medicine, University of
Calgary, Calgary, Alberta T2N4N1, Canada.
[2]Inflammation Research Network-Snyder Institute for Chronic Diseases, Cumming School of
Medicine, University of Calgary, Calgary, Alberta T2N4N1, Canada.
[3]Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta T2N4N1,
Canada.
[4] Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta
T2N4N1, Canada.
[5] Toulouse Institute for Infectious and Inflammatory Diseases (INFINITy), INSERM UMR1291,
CNRS UMR5051, University of Toulouse III, Toulouse, France.
[6]Institute of Functional Genomics, Montpellier University, CNRS, INSERM, Montpellier, France.
[7] Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
02115
23

[$] These authors contributed equally to this work.
*Corresponding author: Christophe Altier, PhD, Professor, Department of Physiology &
Pharmacology, Inflammation Research Network, Snyder Institute for Chronic Diseases,
University of Calgary, HS 1665, 3330 Hospital Dr. N.W, Calgary, AB, T2N4N1 CANADA,
Email: altier@ucalgary.ca, Phone: + 1 (403) 220-7549.

Author contributions:

Conceptualization: MD, AB, CA

Experimental design and Methodology: MD, AB, FA, CA

Investigation: MD, AB, FA, NA, MI, KS, GG, NG, JM, LB, MC, IC

Visualization: CA

Funding acquisition: CA

Project administration: CA

Supervision: CA

Writing – original draft: MD, AB, IC, CA

Acknowledgments:

This work was supported by operating grants from the Crohn's and Colitis Canada (CCC) grant
(CA) and The Canadian Institutes of Health Research (CIHR) grant # 388441 (CA). MD holds a
Postdoctoral Fellowship Support from the Alberta Children's Hospital Research Institute
(ACHRI). FA was sponsored by the Eyes High fellowship initiative at U of Calgary. NA holds the
Association of Gastroenterology (CAG) scholarship.

We would like to thank Dr. F. Jirik and Carolina Salazar for providing the STING-/- [Tmem173gt
C57BL/6J] and the flox-GOF [B6N.CAG-loxP-STOP-loxP-constitutively-active-hSTING-N154S
mutant-IRES-TdTomato] mice; and Frank Visser for producing the AAVs. We thank Dr. Clifford
Woolf for generous support of this project and feedback. We thank the Animal care facility of U
of Calgary for their assistance in mice care, the Clara Christie Centre for Mouse Genomics
(CCCMG), the Flow Cytometry facility of the Snyder Institute and the Centre for Health Genomics
and Informatics (CHGI).

Abstract (up to 150 words, unreferenced)

Nociceptive neurons respond to inflammation, initiating protective reflexes and alerting the host. Here we found that TRPV1 nociceptors express and activate the cytosolic DNA-sensing protein Stimulator of Interferon Genes (STING) in response to inflammation. Neuronal activation of STING promotes signaling through TBK1 and triggers a Type I interferon (IFN-I) response. The absence of STING led to heightened pain responses to chemical irritants or heat. In contrast, mice expressing a nociceptor-specific gain-of-function mutation in STING exhibited an IFN gene signature that reduced nociceptor excitability and inflammatory hyperalgesia. Importantly, several IFN-regulated genes (IRGs) were specific to nociceptor ion channels responsible for controlling neuronal activity and pain threshold. Therefore, STING promotes a pain-resolving IFN-I signaling pathway in nociceptors, thereby preventing sensitization and persistent pain.

Main text – up to 4,500 words, excluding abstract, Methods, references and figure legends.

Introduction

Pain and inflammation are two integrated biological responses that serve as the main defense mechanisms during injury or infection. Inflammatory pain is adaptive and protective; however it often persists even after the inflammation has subsided. While it is well established that activated immune cells contribute to acute pain [1,2], recent studies suggest that acute inflammation can also be protective against the transition to chronic pain [3]. Therefore, understanding how pain resolves is crucial for preventing the development of chronic pain.

Like the immune system, the nociceptive system alerts the host to the presence of "danger signals" [4], and certain pathogens have evolved mechanisms to disable sensory modalities, such as smell, taste [5–7] and even pain [6], by targeting danger signal receptors. Nociceptors have the ability to respond to pathogen/damage-associated molecular patterns (PAMPs/DAMPs) through various pattern recognition receptors (PRRs) [8]. Toll-like receptors (TLRs), Nod-like receptors (NLRs), RIG-I-like receptors (RLRs), and cytosolic DNA sensors (CDSs) have been reported to be expressed in dorsal root ganglion neurons [8].

Among these receptors, Stimulator of Interferon Genes (STING) is a cytosolic DNA sensor that plays a role in recognizing self-DNA, viral DNA, and cyclic dinucleotides (CDN: c-di-GMP, 3'3'-cGAMP and c-di-AMP) produced by bacteria. STING activation leads to the production of Type I interferons (IFN-I) such as interferon α (IFN α) and interferon β (IFNβ) isoforms. Bacterial and host-derived CDNs induce STING dimerization, which activates TANK Binding Kinase 1 (TBK1). TBK1 phosphorylates interferon regulatory factor 3 (IRF3), leading to the production of IFN-I and other genes involved in host responses, promoting elimination of pathogens and damaged host cells upon inflammation [9]. IFN-I bind to IFNα/β receptor (IFNAR) on producer and nearby cells. This autocrine and paracrine stimulation leads to the transcriptional regulation of a wide array of IFN-stimulated genes (ISG) that ordinarily protect cells from infection. Although IFNs were discovered owing to their antiviral properties, they are currently approved for treating a variety of diseases including hepatitis, multiple sclerosis, and melanoma [10].

Recently, STING has been identified as a regulator of nociception [11–15]. Mice lacking STING developed mechanical allodynia, while STING agonists produce anti-nociceptive effects in neuropathic pain models[11]. Treatment with the STING agonist ADU-S100 increases IFN-I levels

in the cerebral spinal fluid (CSF) and reduces the excitability of dorsal root ganglia (DRG) neurons,

indicating the potential of targeting STING for pain management in humans [11].

Despite the role of STING in nociception, the specific mechanisms by which STING modulates

and reprograms nociceptors in inflammatory pain remains unclear. Here, we found that

inflammation induced by Complete Freund Adjuvant (CFA) leads to an upregulation of STING in

Nav1.8+ and TRPV1+ neurons. We show that mice expressing a TRPV1 nociceptor-specific gain-

of-function mutation in human STING exhibited an IFN gene signature associated with reduced

heat hyperalgesia under inflammatory conditions. Interestingly, several IFN-regulated genes

(IRGs) were identified as nociceptor-specific ion channels involved in the control of neuronal

excitability and hyperalgesia. Overall, these findings suggest that STING serves as a marker of

nociceptor sensitization, and IRGs play a crucial role in regulating persistent pain conditions.

Results (with subheadings) (Display items – 3-8 items (figures and/or tables).

Nociceptor STING is upregulated in response to inflammation.

Unmyelinated, small-diameter sensory neurons (C-fibres) undergo significant molecular and morphological changes during injury and inflammation. These processes lead to both temperature and mechanical hypersensitivity [16,17]. To assess the underlying transcriptional changes of small size DRG neurons in response to inflammation, we used Nav1.8 Tg-TdTomato mice which mark neurons that express the voltage-gated sodium channel Nav1.8 (Scn10A)[18]. We used the well-established inflammatory pain model of Complete Freund's Adjuvant (CFA), which induces local inflammatory responses to the injection of heat-killed Mycobacterium tuberculosis. Following intraplantar injection, we FACS sorted Nav1.8+ neurons (**Supp Fig. 1A**) from paw-innervating ipsilateral and contralateral lumbar (L4-L6) DRGs (**Fig. 1A**). Transcriptional analysis identified two differentially expressed genes, between ipsilateral and contralateral sides: STING (Tmem173 gene) and Angiopoietin-like protein 2 (Angptl2) (**Fig. 1B**).

To narrow down our analysis to TRPV1+ nociceptors that play a central role in inflammatory hyperalgesia [19], we repeated the experiment using a TRPV1-ecGFP mouse previously characterized [20](**Supp Fig. 1B, Fig. 1C**). As observed with the larger population of Nav1.8+ neurons, we found that CFA inflammation enhanced STING expression in ipsilateral TRPV1+ neurons (**Fig. 1D**). Co-immunostaining of STING and TRPV1-ecGFP in lumbar ganglia from CFA-treated animals (**Fig. 1E**), validated the transcriptomic data and showed an increase in STING protein level in ipsilateral TRPV1+ neurons (**Fig. 1F**).

Analyzing a single cell RNA sequencing dataset of mouse DRG neurons [21], we found that STING was co-expressed with peptidergic nociceptor-associated transcripts such as Scn10a (Nav1.8), Trpv1, Calca (CGRP), Tac1 (Substance P) and GRFα3 (**Fig. 2A**). We thus performed immunostaining to determine the level of STING protein in the different subpopulations of DRG neurons: TRPV1 (PEP1.1, PEP1.2, PEP1.3, PEP1.4, NP3), GFRα3 (PEP1.1, PEP1.2, PEP1.3, PEP1.4, NP3, TRPM8), GFRα2 (NP1, TH) and IB4 (NP1, NP2, NP3, TH)) (**Fig. 2B**). Immunostaining analysis revealed that STING was enriched in TRPV1+ and GFRα3+ compared to IB4+ and GFRα2+ non peptidergic neurons (**Fig. 2C**). Furthermore, we evaluated the expression of STING in human DRGs (**Fig. 2D**). We found a high degree of colocalization between STING and Nav1.8 transcripts, confirming that STING was enriched in neuronal rather than non-neuronal

cells of human DRGs (**Fig. 2E**). Collectively, our results demonstrated that STING is expressed

in both human and mouse nociceptors.

Neuronal STING activation induces Type I IFN response.

Activation of STING in immune or epithelial cells, drives the production of type I interferons

(IFN-α and IFN-β) and inflammatory cytokines. This IFN-I response is mediated by the

recruitment of TANK-binding kinase 1 (TBK1) and its phosphorylation[22]. We investigated

whether the activation of STING could induce the TBK1 downstream signaling pathway in

TRPV1+ neurons. Cultured DRG neurons were treated with the STING agonist, ADU-S100,

which resulted in the phosphorylation of TBK1 in WT but not in STING-/- neurons (**Fig. 3A-B**).

Additionally, ADU-S100 stimulation led to the production of IFN-β, but not IFN-α, and this IFN-

I response was dependent on the presence of STING (**Fig. 3C-D**). Thirteen distinct cell clusters

have been identified in the DRG [23], including macrophages, fibroblasts and satellite glial cells,

which express STING (http://mousebrain.org/) [21]. To assess the proportion of IFN-β produced by

TRPV1-expressing neurons among all DRG cells, cultures were treated with Resiniferatoxin

(RTX) to ablate TRPV1+ neurons prior to ADU-S100 exposure. RTX pre-treatment reduced the

amount of IFN-β produced in response to the STING agonist by 50%, indicating that a substantial

amount of IFN-I originated from TRPV1+ neurons (**Fig. 3E**).

STING/IFN-I/IFNAR1 signaling axis regulates thermal hyperalgesia.

We then investigated the role of STING in behavioral pain responses to noxious stimuli (i.e.

capsaicin and heat). Intra-plantar injection of the pain-inducing TRPV1 agonist capsaicin (1.6µM)

evoked greater nocifensive responses (including brisk paw withdrawal, licking, or shaking of the

paw) in STING-null animals (**Supp Fig. 2A-B**). Moreover, heat sensitivity was enhanced (**Supp

Fig. 2C**), indicating that STING regulates the threshold of chemical and thermal nociception.

Notably, these results were observed in a sex-independent manner, with both males and females

showing enhanced sensitivity. To investigate the functional impact of STING on nociceptors, we

performed electrophysiological recordings of STING-/- nociceptors (**Supp Fig. 2D**). We first

measured Rheobase as a surrogate of neuronal excitability. The Rheobase decreased marginally,

though not significantly, in STING-/- neurons compared to controls (WT) (**Supp Fig. 2E**).

Similarly, the number of action potentials (AP) evoked by depolarizing current was slightly
elevated in STING-/- neurons compared to controls (WT) (**Supp Fig. 2F**).

To investigate the contribution of neuronal STING-IFN pathway in regulating nociceptive
behaviors, we expressed a STING gain of function (GOF) mutant in TRPV1 neurons. The hSTING
mutation (N154S) has been reported in STING-associated vasculopathy with onset in infancy
(SAVI), a type I interferonopathy associated with constitutive activity of STING [24]. We generated
TRPV1cre-GOF cKI mice by crossing hSTING-N154S mice with TRPV1-Cre animals (**Fig. 4A**).
When assessing the efficiency of Cre recombination and the expression of hSTING-N154S in
TRPV1+ neurons (**Supp Fig. 3A**), we found a high degree of colocalization between hSTING and
TRPV1 nociceptors (**Supp Fig. 3B**). We next examined the expression of TdTomato in the central
terminals of nociceptors in the superficial dorsal horn of the spinal cord (**Supp Fig. 3C**).
Immunohistochemical analysis led to two observations: 1) hSTING-N154S expression occurs
mainly in Substance P (peptidergic) and GFRα3 (peptidergic) nociceptors, with fewer GFRα2
(non-peptidergic) nociceptors (**Supp. Fig. 3C**); and 2) the neuroanatomical organization of
peptidergic and non-peptidergic fibers was conserved in TRPV1cre-GOF mice. We then assessed
how GOF mutation changed STING function in TRPV1cre-GOF animals. Cultured DRG neurons
from TRPV1cre-GOF mice exhibited an elevated level of type I IFNα and β in the absence of
STING stimulation. In addition, ADU-S100 induced a >ten-fold increase in IFNβ, but not IFNα,
compared to untreated neurons (**Fig. 4B and C**). Finally, the ADU-induced increase of both α and
β IFN was six-fold larger in cKI animals versus littermate controls (**Fig. 4B and C**).

We then wanted to determine whether constitutive STING/IFN-I signalling could affect sensory
or pain-like behaviors. While baseline mechanical sensitivity was not altered in naïve TRPV1cre-
GOF mice (**Supp Fig. 4A)**, thermal sensitivity as measured by both the Hot plate and Hargreaves
test was lower than littermate controls (**Fig. 4D and E**). In addition, stereotypical mouse behaviors
such as climbing, rearing, eating, drinking, grooming, scratching and distance moved were normal
in TRPV1cre-GOF cKI animals (**Suppl Fig. 4C-J**), indicating that STING/IFN-I activation in
TRPV1+ neurons only altered thermal nociception.

We next assessed the thermal hyperalgesia of TRPV1cre-GOF mice after CFA. Although a slightly
more pronounced inflammatory response was observed in the ipsilateral paw of TRPV1cre-GOF
mice compared to littermate controls (**Fig. 4F**), TRPV1cre-GOF mice exhibited negligible
inflammatory thermal hyperalgesia (**Fig. 4G**), while mechanical allodynia remained unaffected

(**Supp Fig. 4B**). This analgesic effect was not due to a systemic release of IFN-I or a change in pro- or anti-inflammatory cytokines (**Supp Fig. 5A-F, Table S1**). To assess if the type I IFN receptor (IFNAR1) mediated the anti-hyperalgesic effect of STING-GOF, we used an αIFNAR1 blocking antibody (MAR1). TRPV1[cre]-GOF mice received intrathecal injections of MAR1 antibody (1 µg in 10 µl) or IgG control (1ug in 10 µl) prior to, and three days following CFA injection. Inhibition of IFNAR1 by MAR1 antibody restored thermal hyperalgesia in CFA-treated TRPV1[cre]-GOF mice (**Fig. 4H**). Because IFNAR1 is expressed in both neuronal and non-neuronal cells of the DRG [11,21], we assessed the specific role of IFNAR1 expressed in TRPV1+ fibers by deleting IFNAR1 specifically in TRPV1 nociceptors. TRPV1[cre]-GOF neonates (P5) received either an i.p. injection of AAV expressing Cre-inducible IFNAR1- shRNA or Scr control (**Fig. 4I**). At six weeks, we confirmed that neurons expressing the STING-GOF mutant were infected with the viral construct (**Supp Fig. 6A**). Downregulation of IFNAR1 transcripts was demonstrated by RNAscope, validating the efficacy of the IFNAR1-shRNA vector (**Supp Fig. 6B**). Depletion of IFNAR1 in TRPV1[cre]-GOF neurons restored normal thermal sensitivity (**Fig. 4J**). Importantly, mice treated with IFNAR1-shRNA displayed thermal hyperalgesia compared to IFNAR1-Scr mice after CFA injection (**Fig. 4K**). Overall, these results show that activation of neuronal STING might promote resolution of pain after inflammation, at least in part via autocrine type I IFN-IFNAR1 signaling.

Interferon stimulated genes reduce intrinsic excitability of nociceptors.

To evaluate the effect of IFN-I signaling on nociceptors, we conducted bulk RNAseq on DRG from TRPV1[cre]-GOF mice. Comparative transcriptomic profiling showed a marked interferon signature associated with a dozen of downregulated genes and >100 upregulated Interferon Stimulated Genes (ISGs) in DRGs from naïve TRPV1[cre]-GOF cKi mice, compared to GOF littermate controls (**Fig. 5A**). Among upregulated genes, we found classical ISGs known to trigger protective defense mechanisms against pathogens or tumors: OASL, IFITM3, ISG15, CCL5, USP18 mRNAs. These findings indicated that constitutive activation of STING effectively promoted ISG expression in TRPV1 nociceptors, thus validating our TRPV1[cre]-GOF cKi model to study the interferon gene responses in these neurons. While the function of ISGs enables host defense, and allows cells to recover to normal function, only a handful of these genes have been studied in detail [10], and none of them in the context of neuronal plasticity. Interestingly, nociceptor-specific ion channels, including TRPV1, TRPA1 and TRPC3, were downregulated in TRPV1[cre]-

GOF DRGs, whereas the A-type Kv channel regulating protein (KChIP1) known to suppress
excitability, was upregulated (**Fig. 5A**). Gene expression quantification by qPCR confirmed the
increase in OASL2 (**Fig. 5B**), ISG15 (**Fig. 5C**), and Kcnip1 (KChIP1) (**Fig. 5D**) in TRPV1[cre]-GOF
neurons, whereas TRPV1 expression was significantly reduced (**Fig. 5E**). To investigate the
functional impact of ISGs on nociceptors, we performed electrophysiological recordings of
TdTomato+ TRPV1[cre]-GOF nociceptors (**Fig. 6A**). While the AP amplitude (**Supp Fig.7A**) and
the resting membrane potential (RMP) (**Supp Fig.7B**) were unchanged, an increase in Rheobase
(**Fig. 6B**) and Rin (**Supp Fig.7C**) were measured in TRPV1[cre]-GOF neurons compared to
littermate controls (GOF). In contrast, the rheobase of non-peptidergic IB4+ neurons from
TRPV1[cre]-GOF mice were similar to IB4+ neurons isolated from littermate controls (**Fig. 6B and**
Supp. Fig. 8), suggesting that STING-induced hypoexcitability was specific to TRPV1 neurons in
TRPV1[cre]-GOF mice. Similarly, the number of AP evoked by depolarizing current was lower in
TRPV1[cre]-GOF compared to littermate control neurons (**Fig. 6C**). Lastly, when looking at the AP
half width, TRPV1[cre]-GOF mice had a shorter AP duration, indicating larger hyperpolarizing K+
currents in TRPV1[cre]-GOF neurons (**Fig. 6D-E**). Given that TRPV1 gene expression was reduced
in TRPV1[cre]-GOF DRGs (**Fig. 5A**), we assessed capsaicin-evoked currents in isolated DRG
neurons. We found a pronounced decrease in TRPV1 current density (**Fig. 6F-G**), which was
associated with a reduction in TRPV1 protein level in small size DRG neurons from TRPV1[cre]-
GOF mice (**Fig. 6H-I**). Notably, other neuronal markers, such as GFRa3, SP or GFRa2 were
similar in TRPV1[cre]-GOF compared to littermate neurons (**Supp Fig.9 A-C**). Consistent with the
observation of KChIP1 upregulation by sequencing (**Fig.5A**), we found that KChIP1 protein level
was augmented in TRPV1[cre]-GOF lumbar DRGs (**Fig. 6J-K**). As KChIP1 serves as a specific β-
subunit for Kv4 channels [25,26], we analysed the electrophysiological properties of A-type Kv
currents in TRPV1[cre]-GOF neurons. Notably, the Kv4-mediated A-type current was larger in
TRPV1[cre]-GOF neurons (**Fig. 6L-M**), supporting an increase in Kv4 channel opening or surface
trafficking, induced by KChIP1 upregulation. Accordingly, the steady-state activation of A-type
Kv4 channels was shifted to more hyperpolarized potentials (**Fig. 6N**), while the steady state
inactivation was delayed in TRPV1[cre]-GOF neurons (**Fig. 6O**), indicating a regulation of Kv4
channels by KChIP1. Taken together, our results show that ISGs regulate the expression of ion
channels and channel-interacting proteins to enhance the threshold of nociceptor activation and
reduce the excitability of nociceptive neurons.

IFNAR1 depletion normalizes ion channel expression and electrophysiological properties.

To understand if the electrophysiological phenotype of TRPV1[cre]-GOF neurons was mediated by
IFN-I/IFNAR1 signaling, TRPV1[cre]-GOF neonates (P5) received either an i.p. injection of Cre-
inducible AAV expressing IFNAR1-shRNA or Scr control. Depletion of IFNAR1 in TRPV1[cre]-
GOF neurons restored normal KChIP1 expression (**Fig. 7A-B**). Then, DRG neurons were
dissociated and electrophysiological recording of AAV-infected or non-infected TRPV1[cre]-GOF
neurons was performed (**Fig. 7C**). Notably, IFNAR1-shRNA infected neurons had a much lower
Rheobase compared to non infected or IFNAR1-scr infected TRPV1[cre]-GOF neurons (**Fig. 7D**).
This was consistent with an increase in evoked AP firing observed in IFNAR1-shRNA infected
TRPV1[cre]-GOF neurons (**Fig. 7E**). In addition, IFNAR1 depletion was able to restore TRPV1
current density (**Fig. 7F-G**) and reduce Kv4-mediated A-type current (**Fig. 7H-I**) induced by
STING.

KChIP1/Kv4 interaction promotes the antinociceptive effect of ISGs.

Our results indicate that Kcnip1 (KChIP1) is a key interferon-regulated gene in response to
nociceptor STING activation. Since we observed an increase in A-type K+ current and KChIP1 is
an integral subunit component of the native Kv4 channel complex, we wondered how the Kv4-
KChIP1 subunit complex could contribute to the antinociceptive effect of ISGs. To investigate
this, we first tested Ammtx3, a specific Kv4 channel blocker. In TRPV1[cre]-GOF nociceptors,
Ammtx3 decreased the high Rheobase, (**Fig. 8A-B**), prolonged the AP duration (**Fig. 8C**) and
reduced A-type Kv current density (**Fig. 8D-E**), suggesting an IFN-I dependent upregulation of
A-type K+ current induced by the interaction between KChIP1and Kv4.
To test this hypothesis, we used a TAT-conjugated KChIP1 interfering peptide to disrupt the
KChIP1-Kv4.3 or KChIP1-Kv4.1 subunit complex. Intrapipette administration of the KChIP1
peptide (20nM) in TRPV1[cre]-GOF neurons, led to a gradual reduction of the high Rheobase, over
time (**Fig. 8F**). The effect of KChIP1 peptide was significant after 20 min and reached saturation
at 45 min post-infusion. In contrast, no time dependent inhibition of the rheobase was observed
with a heat-denatured KChIP1 peptide or in the absence of KChIP1 upregulation (GOF littermate
neurons) (**Fig. 8F-G**). Having validated the efficacy of the KChIP1-Kv4 disrupting peptide, we
investigated whether we could target the subunit association in TRPV1[cre]-GOF mice. Intrathecal

infusion of KChIP1 peptide, at 5 and 10 µg, revealed thermal hyperalgesia for three hours, in TRPV1[cre]-GOF mice, following intraplantar CFA (**Fig. 8H**). The same peptide, administered to GOF littermates, did not disrupt CFA-induced hyperalgesia. Together, our results establish that the KChIP1-Kv4 interaction is responsible for the IFN-I-induced antinociception, downstream of neuronal STING.

Discussion

Here we identified STING, a cytosolic DNA sensor expressed on TRPV1 peptidergic nociceptors, as a modulator of neuronal activity and inflammatory pain. We showed that tissue inflammation enhances STING in nociceptors. Activation of STING promotes TBK1 signaling and IFN-I response, leading to a nociceptor-specific IFNAR1 dependent reduction in excitability and inflammatory hyperalgesia. We also report that constitutive activation of STING in nociceptor is sufficient to induce anti-viral ISG response, which reprogram nociceptor gene expression profiles (**Fig. 8I**). Our findings highlight STING as a marker of nociceptor sensitization and emphasize the importance of IFN-regulated genes in controlling persistent pain conditions.

Nociceptors are specialized sensory neurons that detect a wide range of danger signals, including those from pathogens or the host, through the expression of PRRs such as STING [8]. The cGAS-STING pathway which detects cytosolic DNA, is evolutionarily conserved among diverse animal lineages [8,22]. Consistent with previous studies [8,21], we found expression of STING in nociceptors of both mouse and human dorsal root ganglion (DRG) neurons. We demonstrate that during inflammation, the expression and activation of STING were upregulated in TRPV1+ neurons, which are responsible for detecting and responding to noxious stimuli. Certain pathogens, such as SARS-CoV-2, have evolved mechanisms to suppress sensory neurons related to smell and taste, and not all viral infections exhibit symptoms. While further investigation is needed to elucidate whether this nociceptor-specific STING-IFN-I signaling contributes to antiviral responses, it might facilitate the resolution of inflammation, leading to the downregulation of pain once the viral infection has been cleared.

STING responds to both self and non-self insults. While complete Freund's adjuvant (CFA), which contains a suspension of heat-killed mycobacteria, enhances IFN-I production, heat-inactivated Mycobacterium tuberculosis (Mtb) does not have the same effect [27,28]. However, the adjuvant activity of CFA stems from its ability to stimulate a local innate immune response, leading to a delayed hypersensitivity reaction and an intense inflammatory response at the site of injection [29]. Interestingly, NF-kB signaling in response to cytokines such as IL-6 or IL-1β, enhances STING-mediated immune responses by inhibiting the microtubule-mediated trafficking of STING from the Golgi apparatus to lysosomes for degradation [30]. Additionally, a burst of mitochondrial reactive oxygen species (ROS), during inflammation, can trigger the opening of the mitochondrial permeability transition pore (mPTP), resulting in the extracellular release of mitochondrial DNA

(mtDNA). Leakage of mitochondrial components into the cytosol acts as damage-associated

molecular patterns (DAMPs), recruiting cGAS-STING and triggering an immune response [31].

Indeed, the production of IL-1β induces the release of mtDNA, which activates cGAS-STING and

enhances IFN-I production [32].

The role of the STING/IFN-I pathway in nociception has been a subject of debate over the

past years. While administration of STING agonists through the central route causes acute

analgesia in naive animals, peripheral STING agonists or IFN-I injection promotes mechanical

allodynia [11,14,33]. Furthermore, STING activation in response to exogenous ligands, acutely reduces

mechanical allodynia in various neuropathic pain models through IFN-I/IFNAR1 signaling [11,12].

To investigate the role of STING activation specifically in neurons, we used a gain-of-function

approach by expressing human N154S STING mutation in TRPV1 nociceptors, resulting in

constitutive IFN-I production. Our findings indicate that IFN-I/IFNAR1 signaling regulates

thermal but not mechanical sensitivity in both naive and inflammatory conditions. These results

support previous studies highlighting the importance of TRPV1 neurons in thermal sensitivity and

hyperalgesia. Accordingly, ablation of TRPV1 neurons or their central terminals in the spinal cord

using chemical or genetic methods, reduces thermal sensitivity, while mechanical sensitivity

remains unaffected, even after sensitization by inflammation or nerve injury [34,35]. Additionally,

chemogenetic inhibition of TRPV1 neurons using the Designer Receptors Exclusively Activated

by Designer Drugs (DREADD) system does not alter mechanical responses [36]. Notably, Yu and

colleagues have identified two peptidergic populations of nociceptors in human DRG that co-

express TRPV1 and TRPA1, but not PIEZO [37], suggesting that, at least in humans, TRPV1 neurons

predominantly respond to noxious thermal and chemical stimuli, while their sensitivity to

mechanical stimuli might be relatively lower.

Strikingly, while the development of thermal hypersensitivity was prevented in mice with

nociceptor-specific hSTING mutation, the oedema caused by CFA was slightly enhanced. Gain-

of-function mutations in STING, including the N154S mutation, underlie a type I interferonopathy

called SAVI (STING-associated vasculopathy with onset in infancy). SAVI is a severe disease

characterized by early-onset systemic inflammation, skin vasculopathy, and interstitial lung

disease (ILD). SAVI patients exhibit high levels of C-reactive protein [38] and upregulated NF-kB

related protein (e.g. IL-6) [39]. Neuronal overproduction of IFN-I may directly impact the immune

system in the periphery. IFN-I has been shown to indirectly inhibit tumor growth by acting on

immune cells. Natural killer (NK) cells, the first line of defense against infections and tumors,

depend on type I IFNs for maturation, activation, and homeostasis in the tumor microenvironment

(TME) [40,41]. IFN-I also promotes dendritic cell maturation and migration toward lymph nodes,

where their activity is enhanced through the cross-presentation of tumor-associated antigens to

CD8+ T cells [42–44]. Additionally, IFN-I may enhance a pro-inflammatory environment by

inhibiting Treg proliferation, function, and recruitment, as observed in the TME [45–47]. Further

studies are needed to elucidate the relative role of neuronal IFN-I in immune responses to

inflammation.

Our findings also highlight IFNAR1 in the STING-IFN pathway. IFNAR is widely expressed in

peptidergic nociceptors and their central terminals in the spinal dorsal horn [14,48]. The localization

of IFNAR1 in the presynaptic terminals suggests a role for STING-IFN-I in regulating

neurotransmitter release. Indeed, Liu and colleagues reported that IFNAR activation inhibits

excitatory synaptic transmission in somatostatin-positive excitatory neurons, by suppressing

glutamate release from presynaptic terminals [48]. Although IFNAR1 expression in nociceptors is

prominent, non-neuronal IFNAR1 may also contribute to the anti-nociceptive effects of IFN-I.

Emerging evidence suggests that spinal cord microglia and astrocytes play important roles in the

regulation of pain hypersensitivity following tissue and nerve injuries [49,50]. Intrathecal

administration of poly I:C, a synthetic dsRNA, increases the expression of IRF-7 and IRF-9,

indicating that both astrocytes and microglia respond to IFN-I [51],[52]. Nevertheless, using nociceptor-

specific AAV to knockdown IFNAR1 in TRPV1[cre]-GOF mice, we found that neuronal type I IFN

suppressed nocifensive behaviors through their cognate IFNAR1 receptor on TRPV1 nociceptors.

Furthermore, comparative transcriptomic profiling of DRGs revealed a marked interferon

signature associated with downregulated genes and upregulated ISGs in response to STING

activation. Among the ISG repertoire, known anti-viral and anti-tumor genes were identified,

including OASL, EIF2AK2 (PKR), Irf7, Ifit1, Ddx58, Usp18 and ISG15. Interestingly, the

eukaryotic initiation factor 2 (eIF2), a key effector of cellular stress responses, participates in the

reduction of protein translation via phosphorylation by PKR. This reduction in protein translation

allows cells to conserve energy and modify gene expression to effectively manage stress conditions

[53]. While exogenous IFN-I does not result in PKR-eIF2a activation in DRG [14], there is evidence

suggesting the involvement of this pathway in the regulation of thermal sensitivity [14,54]. Neurons

may utilize the PKR-eIF2a pathway to modulate ion channel expression, including TRPV1 and

Kv4 channels, and facilitate the resolution of inflammatory hyperalgesia.

One of the ISGs identified in TRPV1[cre]-GOF DRGs was the Kcnip1 gene, which encodes the

KChIP1 auxiliary subunit of voltage-gated potassium (Kv) channels. In line with our findings,

Kcnip1 is a candidate gene involved in heat pain and has been identified to be enriched in TRPV1+

neurons [55–57]. KChIPs and transmembrane dipeptidyl peptidase-like proteins (DPPs) are part of the

Kv4 channel complex that generates A-type K+ currents [58–60] and inhibits nociceptor excitability

below the threshold for action potential generation[61]. KChIP1 modulates the trafficking, voltage-

dependence, and inactivation kinetics of Kv4, thereby affecting the firing patterns and excitability

of sensory neurons [58,62,63]. While Kv4.1 channels are expressed in all DRG neurons, Kv4.3 is

predominantly found in small-diameter neurons [64–66], specifically non peptidergic IB4+ and

peptidergic TRPV1+ neurons but not CGRP+ neurons [64,66–68]. Notably, Kv4.3 channels are

distributed across the entire cell surface of sensory neurons, including their peripheral endings in

the skin [69,70]. Given that Kv4.3 operates within the subthreshold voltage range, this channel may

function in the cutaneous endings to inhibit action potential initiation in response to non-noxious

stimuli. Additionally, Kv4.3 exhibit high temperature sensitivity within a narrow hyperpolarized

voltage range [71], a property that could potentially be influenced by the level of KChIP1 expression.

Our findings demonstrate that constitutive activation of STING and production of IFN-I

specifically reduce the excitability of TRPV1 neurons while leaving the properties of IB4+ neuron

unchanged. This supports a model in which STING-induced KChIP1 expression reduces action

potential initiation in TRPV1+ nociceptors, thereby increasing the activation threshold of

nociceptors to noxious stimuli.

Overall, our results show that acute inflammation drives the activation of STING in TRPV1

nociceptors, leading to the production of IFN-I. This, in turn, stimulates the IFNAR1 receptor

though an autocrine/paracrine process. The induction of this antiviral pain-resolving ISG response

by neuronal IFNAR1 changes the pattern of ion channel expression, counteracting inflammatory

hyperexcitability and restoring the nociceptor threshold. This modulation may occur through the

PKR-eIF2a pathway, resulting in changes in the expression or function of ion channels, such as

TRPV1 and Kv4.3 channels (**Fig. 8I**). However, further studies are needed to elucidate the

downstream signaling pathways and transcriptional changes that mediate the effects of IFN-I in

nociceptors. Additionally, investigating the role of IFN-I/IFNAR1 signaling in other types of

sensory neurons, such as non-peptidergic nociceptors, and in different pain models will be

important for understanding the broader implications of this signaling pathway in pain resolution.

By identifying STING-ISGs as a key pain-resolving response that tunes down nociceptor

excitability in inflammatory pain conditions, we have added an important innate immune molecule

to the core list of pattern recognition receptors (PRRs) that control the integration of pain signals

in primary afferent neurons [12,72–75]. Harnessing the power of IFN-I and ISGs to alleviate

hyperexcitability of nociceptors may provide a unique therapeutic arsenal for managing

inflammatory pain conditions.

Materials and Methods

Mice

Age-matched 6- to 8-week-old littermate mice of both sex were used for experiments. C57BL/6 and B6.Rosa26-TdTomato reporter mice (ai14 strain) were purchased from Jackson Laboratory (Jax strain #007914). Nav1.8-cre transgenic (Tg) mice (also known as SNS-Cre mice) were from Rohini Kuner's lab (U. Heidelberg, Germany) and previously published [18]. Nav1.8-cre Tg mice were bred with ai14 mice to generate Nav1.8-cre/Tdtomato mice. All animal experiments were approved by the institutional animal care and usage committee (IACUC) at Boston Children's Hospital and conducted according to institutional animal care and safety guidelines at Boston Children's Hospital and Harvard Medical School. The STING-/- [Tmem173gt C57BL/6J] and the flox-GOF [B6N.CAG-loxP-STOP-loxP-constitutively-active-hSTING-N154S mutant-IRES-TdTomato] mice were provided by Dr. F. Jirik (University of Calgary), the TRPV1-cre and TRPV1-eGFP mice [20] were bred at the University of Calgary Animal Resource Center. All mice were genotyped with the primers reported in **Table S2**. To study the gain of function of STING in TRPV1 neurons, TRPV1-Cre+/− mice were bred with flox-STING- hN154S mice to generate TRPV1 neurons expressing GOF (TRPV1-Cre+/-;hSTING-N154S+/- or TRPV1[cre]-GOF) mice and control (TRPV1-Cre-/-;hSTING-N154S+/- or GOF) littermates. All mice were housed under standard conditions with both drinking water and food available *ad libitum*. All experiments were conducted according to the protocols approved by the University of Calgary Animal Care Committee (AC19-0169) and the guidelines of the Canadian Council on Animal Care.

Genotype	Sequence 5' --> 3'	Primer Type
STING-/-	CAGGGAGCCGAAGACTGTCCAT	Forward
	CTGATGCCCGCTTCCTAACT	Reverse
Flox-hSTING-N154S	ATACCTTTCTGGGAGTTCTCTGCTG	Forward
	CACACACCAGGTTAGCCTTTAAGC	Reverse
	GGGCGTACTTGGCATATGATACAC	Reverse
TRPV1-cre	GCG GTC TGG CAG TAA AAA CTA TC	Mutant Forward
	GTG AAA CAG CAT TGC TGT CAC TT	Mutant Reverse

	TTC AGG GAG AAA CTG GAA GAA	Wild type Forward
	TAG TCC CAG CCA TCC AAA AG	Wild type Reverse

Table S2. Primer sequences

Treatment with chemicals, antibodies and viral constructs

Complete Freund's Adjuvant injections- Mice were anesthetized by isoflurane and injected in the right hind paw with 20 µl of Complete Freund's Adjuvant (CFA, purchased from Sigma) using a Hamilton syringe fitted with a 30-gauge needle. Paw oedema was measured with an electronic caliper.

AAV injections- Adeno associated virus (AAV2-PHP.S) was used for expression of IFNAR1-shRNA1-3 in TRPV1[cre-]GOF cKI animals. AAV2-CW3SL-CAG-DIO-IFNAR1-shRNA1-3-eGFP and AAV2-CW3SL-CAG-DIO-IFNAR1-scr-eGFP (2-5E13 GC/mL) were produced at the University of Calgary, Alberta, Canada. Newly born pups (postnatal day 5) were administered 10 µl (intra-peritoneal) of the viral construct at 1E13 GC/mL using a Hamilton syringe connected to a 30G syringe tip (Becton Dickinson). Pups were returned to their parent cages and weaned after 21 days.

Neutralizing antibodies-Anti-mouse monoclonal IFNAR1 neutralizing antibody (MAR1, I-401; 300 ng/mouse, i.t.; PBL Assay Science, 32400-1) and IgG control (I-536) were purchased from Leinco Technologies. Neutralizing antibodies was dissolved in sterile PBS and administered intrathecally. Briefly, mice were anesthetized by isoflurane, the dorsal fur of each mouse was shaved, the spinal column was arched, and a 30-gauge needle was inserted into the subarachnoid space between the L4 and L5 vertebrae. Intrathecal injections of 10 µl were delivered over a period of 5 seconds.

Blocking peptide- The TAT-KChIP1 blocking peptide (YGRKKRRQRRR-AWLPFARAAAIGWMPVA) was purchased from LifeTein. TAT-KChIP1 was dissolved in sterile saline and administered intrathecally (5 and 10 µg in 5ul). For control experiments, the TAT-KChIP1 peptide (10 ug) was denatured at 100°C for 30 min.

Behavioral tests

Capsaicin test-Mice were acclimated to the behavior room for 1 hour and then individually acclimated to plexiglass chambers for 45 minutes. A stock solution of capsaicin (Sigma, M2028) in DMSO (Sigma, D8418) was diluted in saline, and 1.6 µg of capsaicin in 20 µl was intraplantarly injected using a 30G (0.3mm x 13mm) BD PrecisionGlide needle. Mice were immediately placed in the chambers, and their behavior was recorded using a video camera. The number of episodes and the time spent licking, shaking, flinching, and lifting the paw were recorded for 5 minutes.

Evaluation of thermal sensitivity (Hot plate test)-Thermal sensitivity was assessed by using the hot plate test (Bioseb, Pinellas Park, FL). Mice were placed on a metal hot plate set to 52°C ± 0.5°C. The latency from the moment the mouse was placed on the heated surface until it displayed the first overt behavioral sign of nociception, such as lifting or licking a hind paw, vocalization, or jumping, was measured. A timer was used to record the response time, and the mouse was immediately removed from the hot plate after responding or after a maximum cutoff of 30 seconds to prevent tissue damage.

Evaluation of thermal hyperalgesia (Hargreaves test)-Thermal hyperalgesia was examined as previously described [20] by measuring the withdrawal latency of both the right (ipsilateral, i.l.) and left (contralateral, c.l.) hind paws using a focused beam of radiant heat (IR = 30) from a Plantar Test apparatus (UgoBasile). Briefly, mice were individually placed in a small, enclosed testing arena on top of a Plexiglas floor and allowed to acclimate for at least 90 minutes. The Plantar Test apparatus was positioned beneath the animal, so that the radiant heat was directed to the plantar surface of the hind paw. Three trials were performed for each mouse, with a cut-off time set at 15 seconds to prevent tissue damage.

Evaluation of mechanical hyperalgesia (Von Frey)-Mechanical sensitivity was evaluated using the von Frey test by the method of Dixon [76] and adapted by Chaplan et al. [77]. Mice were placed individually in small, enclosed testing arenas on top of a wire grid platform and were allowed to acclimate for a period of at least 90 min before paw withdrawal threshold measurement (PWT). Stimulation was applied using the up-and-down method. Calibrated von Frey filaments, in the range 0.02–1.4 g (Cat no. 58011, Stoelting, IL USA), were applied perpendicularly to the right

hindpaw with sufficient force to cause a slight buckling against the paw for 3–5 s. A positive
response corresponds to a paw withdrawal, flinching, or licking. The PWT was determined as
previously described [77].

Non-evoked pain behavior measurements- Non-evoked pain-related behaviors were assessed
using the noninvasive animal behavior recognition system LABORAS (Metris, Hoofdorp,
Holland). LABORAS is a fully automated behavior recognition and tracking system using
mechanical vibrations to classify different natural behaviors (e.g., eating, drinking, climbing,
locomotion, etc.) and has previously been validated for pharmacological studies [78]. Mice were
placed in the LABORAS cages for a period of 24 h, with drinking water and food available *ad*
libitum and under light/dark cycles.

Mouse DRG neurons
DRG neurons were harvested from mice and enzymatically dissociated in HBSS containing 2
mg/ml collagenase type I and 4 mg/ml dispase (both from Invitrogen) for 45 min at 37 °C. DRGs
were rinsed twice in HBSS and once in Neurobasal A culture medium (Thermo Fisher Scientific)
supplemented with 2% B-27, 10 % heat-inactivated fetal bovine serum (HI-FBS), 100 μg/ml
streptomycin, 100 U/ml penicillin, 50 ng/ml of Nerve Growth Factor (NGF) and 50 ng/ml glial
cell-derived neurotrophic factor (GDNF) (all from Invitrogen). Individual neurons were dispersed
by trituration through a fire-polished glass Pasteur pipette in 4 ml media and cultured overnight at
37 °C with 5% CO_2 in 95% humidity on glass coverslips previously treated with Poly-Ornithine
and Laminin (both from Sigma-Aldrich).

Electrophysiological recordings
DRG neurons were placed in a 1 ml volume chamber and continuously perfused at 1.5 ml/min
with extracellular solution containing (in mM): NaCl 140, KCl 5, $CaCl_2$ 2, $MgCl_2$ 1, Hepes 10, D-
glucose 10, for current clamp recordings. NaCl was replaced by choline for voltage clamp
experiments. Recordings were conducted at room temperature on TdTomato+ neurons identified
using 20x magnification on an inverted epi-fluorescence microscope (Olympus IX51, Olympus
America Inc.). For the identification of the IB4 positive neurons, coverslips were treated with the
plant lectin IB4 conjugated to fluorescein isothiocyanate (IB4-FITC, 10 μg/ml, Invitrogen, I21411)

for 30 min. Whole-cell patch clamp experiments were performed in both voltage-clamp and current clamp mode using a software-controlled Axopatch 200B amplifier in combination with a Digidata 1550A digitizer. Data were low-pass filtered at 5 kHz before being sampled at 10 kHz using Clampex 11 (all from Molecular Devices). Borosilicate glass pipettes (Harvard Apparatus Ltd.) were pulled and polished to 2-3 MΩ resistance with a DMZ-Universal Puller (Zeitz-Instruments GmbH). Patch pipettes contained (in mM): K-gluconate 105, KCl 30, $MgCl_2$ 4, EGTA 0.3, HEPES 10, Na_2ATP 4, Na_3GTP 0.3 and Na-phosphocreatine 10, pH 7.35. All chemicals were purchased from Sigma-Aldrich.

Under voltage clamp control, cells were held at −70 mV and membrane capacitance (Cm) and membrane resistance (Rm) were calculated in response to a -10 mV hyperpolarizing pulse using the Membrane Test function of Clampex. Resting membrane potential (Vm), rheobase (minimum current injection required to elicit an action potential) and resultant action potential amplitude of the neurons were evaluated by switching to current clamp mode, prior to returning to voltage clamp control. Access resitance (Ra) and holding current (Ih) were monitored throughout the experiments to ensure recording stability, and recordings with an unstable Ih or poor Ra (Initial Ra > 20 MΩ or Ra >10% change over the period of recording) were discarded. Data were analyzed from recordings with 75-95% compensation to minimize offsets due to large voltage-clamp errors.

Data analysis, Statistical comparisons

Data were analyzed with Clampfit 11 (Molecular Devices), Easy Electrophysiology (Easy Electrophysiology Ltd) and Prism 9 (GraphPad).

The peak conductance (G) of the potassium current was calculated as follows:

G = Ip/(Vm-EK)

Ip is the peak outward potassium current, Vm is command voltage and Ek is the estimated reversal potential. Activation and inactivation plots were fitted to the Boltzmann relation:

$$f(V) = Gmax/(1 + \exp((V_{1/2} - V)/k))$$

where G_{max} is the maximal conductance, $V_{1/2}$ is the voltage at which activation or inactivation is half-maximal, and k is the slope factor (a positive number for activation, a negative one for inactivation). These parameters were determined from a fit to each experiment, then averaged together to give the mean values (± SEM). To generate averaged, normalised activation and inactivation plots, individual experiments were normalised to G_{max} and averaged together. These

were refitted to the Boltzmann equation; estimates of $V_{1/2}$ and k obtained from these fits differed

from the means mentioned above by < 1 mV.

Type I Interferon measurement

Supernatants of primary DRG neuron cultures were collected 16 hours after stimulation with

ADU-S100 (1 µg/ml; Chemietek, CT-ADUS100). To deplete TRPV1 neurons, the primary DRG

cultures were treated with Resiniferatoxin (1 µM, RTX, Alomone, R-400) for 15 minutes before

ADU-S100 treatment. The concentration of Type I IFN was measured using a Mouse IFN 2-Plex

Discovery Assay® (Eve Technologies). Protein concentration was quantified using a Bradford

assay (Bio-Rad Laboratories) for normalization.

Microarray analysis of Nav1.8Tg-TdTomato Neurons

FACS purification of neurons- 24 hours after CFA injection into the footpad, lumbar (L4-L6)

DRGs ipsilateral to or contralateral to the side of CFA injection were dissected from mice, digested

in 1 mg/mL Collagenase A/2.4 U/mL Dispase II (enzymes from Roche), dissolved in HEPES

buffered saline (Sigma) for 70 minutes at 37°C. For each subsequent microarray sample, DRGs

from n=3 mice each were pooled. Following digestion, cells were washed into HBSS containing

0.5% Bovine serum albumin (BSA, Sigma), filtered through a 70 µm strainer, resuspended in

HBSS/0.5% BSA, and subjected to flow cytometry. Cells were run through a 100 µm nozzle at

low pressure (20 p.s.i.) on a BD FACS Aria II machine (Becton Dickinson, USA). A neural density

filter (2.0 setting) was used to allow visualization of large cells and TdTomato+ cells were gated

on for isolation. For subsequent RNA extraction, fluorescent neurons were FACS purified directly

into 1 mL Qiazol (Qiagen). FACS data was analyzed using FlowJo software (TreeStar, OR USA).

Flow cytometry was performed in the IDDRC Stem Cell Core Facility at Boston Children's

Hospital.

RNA Processing, Microarray Hybridization and Bioinformatics Analysis-Total RNA was

extracted by sequential Qiazol extraction and purification through the RNeasy micro kit with on

column genomic DNA digestion according to the manufacturer's instructions (Qiagen, CA, USA).

RNA quality was determined by Agilent 2100 Bioanalyzer using the RNA Pico Chip (Agilent,

CA, USA). Samples with RIN>7, were used for subsequent analysis. RNA was amplified into

cDNA using the Ambion WT expression kit for Whole Transcript Expression Arrays, with Poly-

A controls from the Affymetrix GeneChip Eukaryotic Poly-A RNA control kit (Affymetrix, CA,

USA). The Affymetrix GeneChip WT Terminal labeling kit was used for fragmentation and biotin

labeling. Affymetrix GeneChip Hybridization control kit and the Affymetrix GeneChip

Hybridization, wash, stain kit was used to hybridize samples to Affymetrix Mouse Gene ST 1.0

GeneChips, fluidics performed on the Affymetrix GeneChip Fluidics Station 450, and scanned

using Affymetrix GeneChip Scanner 7G (Affymetrix). Microarray work was conducted at the

Boston Children's Hospital IDDRC Molecular Genetics Core facility. Affymetrix CEL files were

normalized using the Robust Multi-array Average (RMA) algorithm with quantile normalization,

background correction, and median scaling. Differentially expressed transcripts were illustrated

using volcano plots, generated by plotting fold-change differences against comparison p-values or

–log (p-values).

Microarray analysis TRPV1-pHluorin Neurons

Flow Cytometry-On day 3 of CFA, both ipsilateral and contralateral DRG sample (L4-L6) from

TRPV1-ecGFP mice were collected and digested separately. After digestion, cells were filtered

through a 90 mm mesh (Sarstedt) and washed in PBS 1% FBS. Cells were analyzed on a FACS

Aria II (BD Bioscience). After FACS sorting, RNA was extracted separately from GFP positive

and GFP negative cells using a RNeasy Mini kit (Qiagen). The quantity of RNA was determined

using a Nanodrop 2000c spectrophotometer (Thermo-Fisher Scientific).

RNA Processing, Microarray Hybridization and Bioinformatics Analysis-Three biological

replicates for the GFP positive and GFP negative samples (~50 ng/sample) were submitted to the

Centre for Applied Genomics (Toronto, Canada). Here the quality of the samples was assessed

using the Agilent Bioanalyzer 2100 with the RNA Pico chip kit (Agilent Technologies). RNA

integrity number values between 6.5 and 7 were achieved. The expression profiling was performed

according to the manufacturer's instructions with Affymetrix GeneChip Mouse Gene 2.0 ST Array

(Affymetrix). Primary data analysis was carried out with the Affymetrix Expression Console

1.4.1.46 software including the Robust Multi-array Average module for normalization. Gene

expression data were log-transformed. A change was considered significant when the FDR-

corrected p-value/q-value thresholds met the criterion q < 0.01 at fold changes > 2 (expression

increments or declines larger than two).

RNA sequencing analysis of TRPV1[cre]-GOF Neurons

RNA Processing and sequencing

Neurons-Lumbar (L4-L6) DRGs were dissected from naïve GOF (n = 4) and TRPV1[cre]-GOF mice

(n = 4). Total RNA from was purified through the RNeasy micro kit with on column genomic

DNA digestion according to the manufacturer's instructions (Qiagen, CA, USA). RNA quality was

determined by Agilent Technologies 5200 Fragment Analyzer (Agilent, CA, USA). Samples with

RIN>7, were used for subsequent analysis. cDNA libraries were generated were generated using

the NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina® (New England

Biolabs) on an Illumina NextSeq500.

RNA sequencing analysis

The quality control of reads was performed with FastQC, and all samples passed quality control.

Reads were then aligned with STAR (v2.4.0j) [79] on the Mus musculus genome GRCm39.107 from

EBI databases. Alignment was then converted with SAMtools (v1.16.1) [80], and genes counts were

computed with HTSeq counts (v0.9.1) [81].

Differential Gene Expression analysis - Count matrix from HTSeq-counts were analyzed with

DESeq2 (v1.34.0) [82]. In order to compare samples, raw data were normalized with

rlogTransformation function. A change was considered significant when the adjusted p-value

(Benjamini-Hochberg) thresholds met the criterion p < 0.05 at fold changes > 2 (expression

increments or declines larger than two).

Analysis of published single-cell RNAseq

To analyze STING (TMEM173) expression in peripheral sensory neurons, the «Adolescent, Level

6, Taxonomy Level 2 Pns neurons» dataset from the mouse brain atlas (http://mousebrain.org/)

[21] was extracted and processed using Seurat package (Seurat version 4.1.0) (59) in R (version

4.1.1). Loom files were converted into Seurat object using the LoadLoom function from

SeuratDisk package. Results were then processed with the classical Seurat pipeline. The

expression matrix for each population was computed with AverageExpression function, and the

heatmap was generated using the DoHeatmap function of the mean expression matrix of the list of

gene of interest.

Immunohistochemistry

Animals were perfused with phosphate buffered saline (PBS) to wash out blood and then perfused

with 4% paraformaldehyde (PFA) (Electron Microscopy Science, Cat. No. 15713). Lumbar (L4-

L6) DRGs and spinal cord were extracted and dehydrated overnight in 30% sucrose and embedded

in optimal cutting temperature (OCT) solution (VWR International, Cat. No. 95057-838).

Embedded tissues were sliced 10-μm thick onto SuperFrost slides (VWR International). The

following antibodies were used in this study: chicken polyclonal anti-GFP (1:500, Invitrogen,

A10262), rabbit polyclonal anti-GFP (1:500, Invitrogen, A10262), rabbit polyclonal anti-STING

(1:100, Cell Signaling, 13647S), rabbit polyclonal anti-TRPV1 (1:250, Alomone, ACC-030),

guinea pig polyclonal anti-TRPV1 (1:250, Alomone, ACC-030-GP), rat polyclonal anti-Substance

P (1:500, Millipore, MAB356), IB4-coupled Alexa 594 (1:1000, Invitrogen, I21412), goat

polyclonal anti-GFRα3 (1:500, R&D Systems,VFU021721), goat polyclonal anti-GFRα2 (1:500,

R&D Systems, AF429), donkey anti-chicken Alexa Fluor 488 (1:1000, Invitrogen, SAB4600031),

goat anti-rabbit Alexa Fluor 488 (1:2000, Invitrogen, A11008), goat anti-rabbit Alexa Fluor 555

(1:2000, Invitrogen, A21428), chicken anti-goat Alexa Fluor 647 (1:2000, Invitrogen, Cat. No.

A21469;), anti-rat Alexa Fluor 647 (1:2000, Cederlane, 712-605-153).

All sections were mounted using Aqua PolyMount (Polysciences). Confocal images were acquired

on a Zeiss LSM 510 Meta confocal microscope and AxioCam HRm camera and analyzed using a

20× objective. Sections were imaged and analyzed using ImageJ. A minimum of three mice per

group were analyzed.

In situ hybridization

Human DRG neurons- RNAscope in situ hybridization multiplex chromogenic assay was

performed as instructed by Advanced Cell Diagnostics (ACD). Snap frozen human DRG tissues

were cryo-sectionned at 18 μm, mounted on SuperFrost Plus slides (FisherScientific) and stored

at -80°C. The next day, slides were removed from the -80°C freezer and immediately washed with

PBS (pH 7.4; 5 min, twice), fixed with 4% PFA-PBS, and then dehydrated in 50% ethanol (5 min),

70% ethanol (5 min) and 100% ethanol (5 min) at room temperature. Slides were pre-treated with

H2O2 10 min at RT and washed twice in distilled water. Then, slides were submerged in 1X

boiling RNAscope target retrieval reagent for 5 minutes. After target retrieval agent treatment,

slides were transferred in distilled water and then washed in 100% ethanol. The slides were air

dried briefly and then boundaries were drawn around each section using a hydrophobic pen

(ImmEdge PAP pen; Vector Labs). When hydrophobic boundaries have dried, protease III reagent

was added to each section and slides were incubated for 20 min. at 40°C in a HybEZ oven (ACD).

This last step was repeated once, and slides were washed with distilled water before RNAscope

assay. The RNAscope assay was performed according to the manufacturer's instructions using a

HybEZ oven (ACD). The probes used were Hs-TMEM173 (ACD, # 433541), Hs-Scn10a (ACD,

#406291-C2). At the end of the process, hematoxylin counterstain was performed (30% Gill

hematoxylin n°1; Sigma) and slides were mounted with Vectamount mounting medium (Vector

Labs). Slides were imaged at 40x with Hamamastu Nanozoomer 2 slide scanner.

Mouse DRG neurons- Co-detection of RNAscope in situ hybridization multiplex v2 fluorescent

assay (ACD, #323110) combined with immunofluorescence was performed on mouse DRG

neurons. Mice were euthanized with isoflurane and then perfused with PBS followed by 4% PFA

as described above. DRGs were extracted and placed in 4% PFA overnight at 4°C followed by

30% sucrose overnight at 4°C and then embedded in OCT and stored at -80°C. OCT sections were

cut into 10μm slices onto SuperFrost slides and stored at -80°C for up to two months. On the day

of the assay, slides were washed In PBS (5 min, twice, RT), baked for 30 min at 60°C and then

post-fixed in pre-chilled 4% PFA in PBS for 15 min at 4°C. The tissue was then dehydrated

sequentially in 50% ethanol (5 min, RT), 70% ethanol (5 min, RT), and 100% ethanol (2 min,

twice, RT). The tissue was then treated with H2O2 (10 min, RT) (ACD, #322335), washed twice

in PBS with 0.1% Tween-20 (PBS-T) (Sigma, #P1379) (5 min, twice, RT), and then a barrier was

created around the tissue using a hydrophobic pen (Vector Labs, #H-4000). The primary antibody,

diluted in Co-detection Antibody Diluent (ACD, #323160) was applied to each section and stored

overnight at 4°C. The following day, the tissue was washed in PBS-T (2 min, twice, RT), and then

submerged in 10% Neutral Buffered Formalin (NBF) (30 min, RT) for post-primary fixation. The

tissue was then washed in PBS-T (2 min, 4 times, RT), RNAscope Protease Plus (ACD, #322331)

was applied to the tissue for 30 min at 40°C. The RNAscope assay was then performed according

to ACD's instructions. At the end of the assay, before mounting the slides, the secondary antibody was added to the tissue for 30 min at RT before the slide was washed in PBS-T (2 min, twice, RT). The slides were then mounted using ProLong Gold antifade reagent with DAPI (Invitrogen, #P36931). The probes used were Mm-Trpv1 (ACD, #313331-C2), Mm-Kcnip1 (ACD, #466891-C3), Hs-TMEM173 (ACD, #433541), and Mm-Ifnar1 (ACD, #512971) and were labelled using TSA Vivid Fluorophores 570 (ACD, 323272) and 650 (ACD, #323273). The primary antibody used was anti-GFP (Chromotek, #PABG1) and the secondary antibody was Alexa Fluor 488 donkey anti-rabbit IgG (Invitrogen, #A21206). The tissue was imaged using the Leica SP8 confocal microscope at 20x or 63x objectives.

Western Blot Analysis

TBK1 expression-To look at the phosphorylation of TBK1, we performed primary DRG neurons culture from WT and STING-/- mice and stimulated them with 10 µg/ml ADU-S100 for three hours. DRGs were homogenized using a bullet blender (Next Advance) with SSB02 beads (Next Advance) and lysed in RIPA buffer with protease and phosphatase inhibitors (Thermo Scientific) for 45 minutes. Lysates were centrifuged at 10,000g for 10 min at 4°C, supernatants were collected, and protein concentration was quantified and normalized using a Bradford assay (Bio-Rad laboratories). Total lysates were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Sigma-Aldrich). Membranes were blocked in 5% BSA 1h at room temperature, and then probed with anti-phospo-TBK1 antibody (1:200 dilution in 1% BSA, Cell Signalling, 5483S) at 4°C overnight. Membranes were then washed three times with TBS-T and incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit antibodies (1:1000 in 1% BSA; Cederlane, NA934) for 1h at room temperature. Bands were visualized using the Immobilon Western chemiluminescent HRP Substrate (Bio-Rad Laboratories), and band density was calculated using Image J. Intensity of anti-TBK1 antibody (1:1000 dilution in 1% BSA; Cell signalling, 3504S) band was used for normalization among samples.

KChIP1 expression- DRGs were homogenized using a bullet blender (Next Advance) with SSB02 beads (Next Advance) and lysed in RIPA buffer with protease and phosphatase inhibitors (Thermo Scientific) for 45 minutes. Lysates were centrifuged at 10,000g for 10 min at 4°C, supernatants were collected, and protein concentration was quantified and normalized using a Bradford assay

(Bio-Rad laboratories). Total lysates were separated by SDS-PAGE and transferred onto
nitrocellulose membranes (Sigma-Aldrich). To investigate the level of KChIP1 protein,
membranes were blocked in 5% BSA 1h at room temperature, and then probed with anti-KChIP1
antibody (1:250 dilution in 1% BSA, Alomone, APC-141.) at 4°C overnight. Membranes were
then washed three times with TBS-T and incubated with horseradish peroxidase (HRP)-conjugated
anti-rabbit antibodies (1:1000 in 1% BSA, Cederlane, NA934) for 1h at room temperature. Bands
were visualized using the Immobilon Western chemiluminescent HRP Substrate (Bio-Rad
Laboratories), and band density was calculated using Image J. Intensity of Rabbit anti-Beta-tubulin
III antibody (1:1000 dilution in 1% BSA; Sigma-Aldrich, T2200) band was used for normalization
among samples.

Cytokine profiling
Blood samples were centrifuged (5000 x g, 30 minutes, 4°C) and then serum was processed using
both a Mouse IFN 2-Plex Discovery Assay® and a MILLIPLEX Mouse Cytokine Array
Proinflammatory Focused 10-plex (Eve Technologies).

qPCR
DRGs were harvested and dissociated using a bullet blender (Next Advance) with SSB02 beads
(Next Advance) in RLT buffer (Qiagen). Total RNA was extracted using a RNeasy Mini kit
(Qiagen), according to the manufacturer's instructions. The quality and quantity of RNA were
determined using a Nanodrop 2000c spectrophotometer (Thermo-Fisher Scientific). Relative gene
expression (normalized to GAPDH) was determined by qPCR using BlasTaq 2X qPCR MasterMix
(ABMgood, G892) and a StepOnePlus real-time PCR detection system (Applied Biosystems). The
designed primers for DNA amplification are listed in Supplemental **Table S3**.

Gene	Sequence 5' --> 3'
OASL2	TTGTGCGGAGGATCAGGTACT
	TGATGGTGTCGCAGTCTTTGA
ISG15	CAATGGCCTGGGACCTAAA
	CTTCTTCAGTTCTGACACCGTCAT

TRPV1	AACAAGAAGGGGCTTACACC
	TCTGGAGAATGTAGGCCAAGAC
KChIP1	CGACCCTCCAAAGATAAGATTG
	AGTTCCTCTCAGCAAAATCGAC
IFNAR1	GCAGTGTGACCTTTTCAGCA
	GAGAATTCACACTTGGTCGTTG
GAPDH	ATGCTGGTGCTGAGTATGTCG
	GTGGTGCAGGATGCATTGCTGA

Table S3. qPCR primer sequences

Data availability

Microarray data from lumbar DRG Nav1.8-cre Tg/TdTomato neurons from CFA ipsilateral and

contralateral sides are deposited at the NCBI GEO database under accession number GSE221834.

Microarray data collected from naïve lumbar DRG Nav1.8-Cre Tg/TdTomato neurons were

previously deposited at GEO database under accession no. GSE46546. Microarray data collected

from lumbar DRG TRPV1-ecGFP neurons from CFA ipsilateral and contralateral sides were

previously deposited at GEO database under accession no. GSE201227. Bulk RNAseq data

collected from lumbar DRG neurons from GOF and TRPV1[cre]-GOF animals were deposited at

NCBI GEO database under accession no. GSE236865.

Statistics

Statistical analyses were performed with GraphPad Prism 7® software. Normal distribution was

verified using D'Agostino-Pearson normality Test. For Gaussian data, Student's t-test was used to

assess statistical significance when comparing two means, One-Way ANOVA followed by the

Tukey *post hoc* test was used to compare more than two groups and Two-way ANOVA followed

by Bonferroni (two groups) and Tukey *post hoc* test (for more than two groups) for multiple

comparisons. For non-Gaussian data, the non-parametric Mann Whitney U test was used to assess

statistical significance when comparing two means, Kruskal-Wallis followed by the Dunn's *post*

hoc test was used to compare more than two groups. Statistical significance was established at P

≤ 0.05. Values were expressed as means ± standard error mean (SEM).

 Figure legends

Figure 1. Transcriptional changes in Nav1.8 and TRPV1 neurons after CFA inflammation.

(**A**) Experimental approach used to isolate Nav1.8Tg-TdTomato neurons for microarray analysis,

24 hours after intraplantar CFA. (**B**) Volcano plot showing transcriptional changes induced by

CFA inflammation in Nav1.8Tg-TdT neurons (n = 3 mice). P-value line cut-off is $p < 0.01$, and fold

change of 2. Select transcripts of interest are highlighted in distinct colors (legend). (**C**)

Experimental approach used to isolate TRPV1-ecGFP neurons for microarray analysis, 72 hours

after intraplantar CFA. (**D**) Volcano plot showing transcriptional changes induced by CFA

inflammation in TRPV1 neurons. P-value line cut-off is $p < 0.05$, and fold change of 1.5. Select

transcript of interest is highlighted in red (legend). (**E**) Representative confocal images of co-

immunostaining for STING and TRPV1-ecGFP in both ipsilateral and contralateral DRG neurons

of CFA-treated mice. Scale bars: 50 µm. (**F**) Dot plot showing the percentage of neurons co-

expressing STING and TRPV1 in DRG from TRPV1-ecGFP mice (from n = 3 mice). Statistical

analysis was performed using Kruskal-Wallis followed by Dunn's post-hoc test (** $p < 0.01$, ***

$p < 0.001$). Results indicate the mean ± SEM.

Figure 2. STING is expressed in mouse and human DRG nociceptors. (**A**) Heatmap of the

expression of STING and selected population markers on the 15 populations of sensory neurons

from DRG described in Zeisel et al., [21]. (**B**) Representative confocal images of co-immunostaining

for STING and IB4, GFRα2, TRPV1 and GFRα3 in mouse DRG neurons. Scale bars: 50 µm. (**C**)

Dot plot showing the percentage of peptidergic (TRPV1, GFRα3) and non-peptidergic (IB4,

GFRα2) neurons co-expressing STING in DRG from TRPV1-ecGFP mice (n = 3 mice). Statistical

analysis was performed using Kruskal-Wallis followed by Dunn's post-hoc test (** $p < 0.01$, ***

$p < 0.001$, **** $p < 0.001$). (**D**) Representative RNAscope image showing expression of STING

(light blue) in human DRG neurons co-expressing Nav1.8 (pink). (**E**) The bar graph summarizes

the results (each symbol represents a single DRG; n = 3 for one patient and n = 4 for another

patient). The results are presented as the mean ± SEM.

Figure 3. Activation of STING induces type IFN-I through TBK1 in nociceptors. (**A**)

Phospho-TBK1 (p-TBK1) protein level was determined by Western blot in the lumbar DRG

neurons culture (L4-L6) treated with Vehicle (n = 3) or ADU-S100 for three hours (n = 3) from

WT and STING-/- mice. (**B**) Bar graph representing p-TBK1 quantification. Data are normalized

to TBK1 signal. Statistical analysis was performed using One-way ANOVA followed by Tukey

post-hoc rest (*** $p < 0.001$). IFNα (**C**) and IFNβ (**D**) levels were determined by Luminex

technology in the DRG culture of WT (n = 4) and STING-/- (n =4-8) DRG cultures treated with

Vehicle or ADU-S100. Statistical analysis was performed using One-way ANOVA followed by

Tukey post hoc test (**** $p < 0.0001$). (**E**) IFNβ levels were determined by Luminex technology

in Vehicle (n = 4) and RTX (n = 3) pre-treated DRG neurons, stimulated with ADU-S100.

Statistical analysis was performed using One-way ANOVA followed by Tukey post hoc test (* p

< 0.05; *** $p < 0.001$; **** $p < 0.0001$). Results indicate the mean ± SEM.

Figure 4. Nociceptor-specific STING-N154S gain of function reduces thermal sensitivity and

heat hyperalgesia in an IFNAR1 dependent manner. (**A**) Schematic representation of the

transgenic TRPV1^{cre}-GOF cKi mouse design. (**B**) IFNα levels were determined by Luminex

technology in DRG cultures of GOF (n = 4) and TRPV1^{cre}-GOF (n = 6) mice and stimulated with

ADU-S100. Statistical analysis was performed using Kruskal-Wallis followed by Dunn's post hoc

test (* $p < 0.05$). (**C**) IFNβ levels were determined by Luminex technology in DRG cultures of

GOF (n = 4) and TRPV1^{cre}-GOF (n = 6) mice and stimulated with ADU-S100. Statistical analysis

was performed using One-Way ANOVA by Tukey post hoc test (** $p < 0.01$; *** $p < 0.001$; ****

$p < 0.0001$). (**D-E**) Measurement of thermal sensitivity in hind paws of naïve TRPV1^{cre}-GOF (n =

15-16) and littermate control GOF mice (n = 7-12) using the Hot plate (**D**) or Hargreaves test (**E**).

Statistical analysis was performed using t-test (**D**) or Mann-Whitney test (**E**) (** $p < 0.01$, **** p

< 0.0001). (**F**) Measurement of edema in the ipsilateral and contralateral hind paws of CFA-treated

GOF mice (n = 9) and TRPV1cre-GOF mice (n = 8). Statistical analysis was performed using One-

Way ANOVA followed by Tukey post-hoc test (** $p < 0.01$, **** $p < 0.0001$). (**G**) Measurement

of thermal withdrawal latency in the ipsilateral and contralateral hind paws of GOF (n = 9) and

TRPV1^{cre}-GOF (n = 8) mice that were treated with CFA. Statistical analysis was performed using

Two-way ANOVA followed by Tukey post-hoc test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). (**H**)

Measurement of thermal withdrawal latency in the hind paws of CFA-treated TRPV1^{cre}-GOF mice

that received either an IgG control (n = 5) or IFNAR1 neutralizing antibody (MAR-1) prior to

CFA injection and at day three post CFA injection (n = 6). Statistical analysis was performed using

Two-way ANOVA followed by Tukey post-hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001, ****

p < 0.0001). (**I**) Newly born pups (postnatal day 5) were administered 10 µL of AAV-PHP.S-DIO-

IFNAR1-shRNA or AAV-PHP.S-DIO-scrambled-shRNA intraperitoneally. (**J**) Measurement of

thermal sensitivity in the hind paws of AAV-DIO-scram-shRNA (n = 9) and AAV-DIO-IFNAR1-

shRNA (n = 16) injected mice. Statistical analysis was performed using t-test (**** p < 0.0001).

(**K**) Measurement of thermal withdrawal latency in the ipsilateral and contralateral hind paws of

AAV-DIO-scram-shRNA (n = 7) and AAV-DIO-IFNAR1-shRNA (n = 9) infected mice treated

with CFA. Statistical analysis was performed using Two-way ANOVA followed by Tukey post-

hoc test (** p < 0.01, **** p < 0.0001 vs AAV-DIO-scram-shRNA i.l.; ($$ p < 0.01, $$$$ p <

0.0001, vs AAV-DIO-scram-shRNA c.l.). Results indicate the mean ± SEM.

Figure 5. Nociceptor-specific STING-N154S gain of function induces IFN-I production and

expression of Interferons Stimulated Genes (ISGs) in DRGs. (**A**) Volcano plot representation

of genes regulated in naive TRPV1^{cre}-GOF cKi mice. Genes that pass a threshold of log1.5-fold

change in differential expression analysis are colored in green when they are downregulated and

red when they are upregulated. (**B**) OASL2 expression in lumbar DRG neurons of naïve GOF (n

= 6) and TRPV1^{cre}-GOF (n = 9) mice. Statistical analysis was performed using t-test (**** p <

0.0001). (**C**) ISG15 expression in lumbar DRG neurons of naive GOF (n = 6) and TRPV1^{cre}-GOF

(n = 9) mice. Statistical analysis was performed using Mann-Whitney test (*** p < 0.001). (**D**)

KChIP1 expression in lumbar DRG neurons of naive GOF (n = 7) and TRPV1^{cre}-GOF (n = 13)

mice. Statistical analysis was performed using t-test (**** p < 0.0001). (**E**) TRPV1 expression in

lumbar DRG neurons of naive GOF (n = 6) and TRPV1^{cre}-GOF (n = 8) mice. Statistical analysis

was performed using t-test (* p < 0.05). Results indicate the mean ± SEM.

Figure 6. **ISGs alter nociceptor properties through TRPV1 downregulation and KChIP1**

expression. (**A**) Representative current clamp recording of evoked action potentials recorded in

TRPV1 neurons (TdTomato+) from GOF (left) and TRPV1^{cre}-GOF (right) mice. Cells were

injected with a 500 ms current pulse with an increment of 10 pA and an interval of 5 seconds.

Scale bars: 20 mV/50 ms. (**B**) Rheobase data recorded in TRPV1 (TdTomato+) and non-

peptidergic (IB4+) neurons from GOF mice (45.33 ± 4.72 pA, n=61 TRPV1+ neurons; 25.63 ±

5.40 pA, n=16 IB4+ neurons) and TRPV1^{cre}-GOF mice (103.70 ± 6.85 pA, n=101 TRPV1+

neurons; 29.09 ± 2.86 pA, n=22 IB4+ neurons). Statistical analysis was performed using the
Kruskal-Wallis test with Dunn's multiple comparison test. **** $p < 0.0001$. (**C**) Number of spikes
as a function of injected current in TRPV1 neurons from TRPV1^{cre}-GOF mice and GOF littermate
controls. Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc
test. (** $p < 0.01$, *** $p < 0.001$). (**D**) Representative action potentials recorded in TRPV1 neurons
from GOF (black) and TRPV1^{cre}-GOF (red) mice. Scale bars: 20 mV/50 ms. (**E**) Action potential
half-width recorded in TRPV1 neurons from GOF (3.86 ± 0.21 ms, n=61) and TRPV1^{cre}-GOF
(2.73 ± 0.82 ms, n=101) mice. Statistical analysis was performed using the Mann-Whitney test.
**** $p < 0.0001$. (**F**) Representative currents induced by 100 nM of capsaicin in TRPV1 neurons
from GOF (left) and TRPV1^{cre}-GOF (right) mice. Scale bars: 200 pA/10 s. (**G**) Current density
evoked by capsaicin in TRPV1 neurons from GOF (-21.93 ± 7.51 pA/pF, n=25) and TRPV1^{cre}-
GOF (-2.85 ± 0.96 pA/pF, n=70) mice. Statistical analysis was performed using the Mann-Whitney
test. **** $p<0.0001$. (**H**) Representative confocal images of TRPV1 immunostaining in lumbar
DRG neurons of naïve GOF and TRPV1^{cre}-GOF mice. Scale bars: 50 µm. (**I**) Size distribution of
the percentage of DRG neurons immunopositive for TRPV1, in naïve GOF (n = 3) and TRPV1^{cre}-
GOF mice (n = 3). Statistical analysis was performed using Two-way ANOVA followed by Tukey
post-hoc test (** $p < 0.01$). (**J**) Western blot of KChIP1 and β-tubulin from lumbar DRG lysates.
(**K**) Quantification of KChIP1 protein level in DRG lysates from naïve GOF (n = 4) and TRPV1^{cre}-
GOF (n = 5) mice, measured by Western blot. Statistical analysis was performed using the Mann-
Whitney test (* $p < 0.05$). (**L**) Representative outward potassium currents recorded in TRPV1
neurons from GOF (left traces) and TRPV1^{cre}-GOF (right traces) mice. Scale bars: 1 nA/100 ms.
(**M**) Current – Voltage relationship from neurons recorded in (L). GOF (n=10) and TRPV1^{cre}-GOF
(n=17). (**N**) Steady-state activation and inactivation (**O**) from neurons recorded in (L). Activation;
GOF: V1/2 = 3.567 mV, K=18.68 mV, n=17; TRPV1^{cre}-GOF: V1/2 = -3.779 mV, K=21.20 mV,
n=17. Inactivation; GOF: V1/2 = -48.31 mV, K=-8.72 mV, n=18; TRPV1^{cre}-GOF: V1/2 = -41.56
mV, K=-13.01 mV, n=25. All steady-state plots were fitted with Boltzmann functions to derive
V1/2 and K values. Statistical analysis was performed using a two-way ANOVA test with Tukey's
post-hoc test. (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). Results indicate the mean ± SEM.
929
930 **Figure 7**. **IFNAR1 depletion in nociceptors restores electrophysiological properties**. (**A**)
931 Representative confocal image of TRPV1 neurons from TRPV1^{Cre}-GOF mice injected with AAV-

DIO-Scr-shRNA (n = 5) or AAV-DIO-IFNAR1-shRNA (n = 5). Images represent DAPI staining, AAV-GFP expression (green) and KChIP1 transcripts (red) by RNAscope. Scale bars: 25 µm and 10 µm on the cropped images. **(B)** Quantification of KChIP1 density measured by the number of transcripts represented by dots per surface unit in AAV-infected TRPV1 neuron. Statistical analysis was performed using unpaired t-test (**** $p < 0.0001$). **(C)** Representative current clamp recording of TdTomato+/GFP+ TRPV1 neurons from TRPV1^{Cre}-GOF mice infected with DIO-Scram-shRNA (left) or DIO-IFNAR1-shRNA (green) AAVs. Cells were injected with 500 ms current pulses with an increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. **(D)** Measurement of Rheobase in infected (GFP+) and non-infected (GFP-) TRPV1 neurons (TdTomato+) recorded in (D). Data are presented as dot plots with mean values (172.8 ± 11.04 pA, n=89 for IFNAR1-Scr neurons; 56.13 ± 2.75 pA, n=80 for IFNAR1-shRNA infected neurons; and 208.30 ± 21.89 pA, n=18 for IFNAR1-Scr neurons; 251.10 ± 24.77 pA, n=18 for IFNAR1-shRNA non-infected neurons). Statistical analysis was performed using the Mann-Whitney test. ****$p<0.0001$. **(E)** Number of spikes evoked by injected current in TRPV1 (TdTomato+) and AAV infected (GFP+) neurons. Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test. (** $p < 0.01$, **** $p < 0.0001$). **(F)** Representative capsaicin-evoked current in TdTomato+/GFP+ TRPV1 neurons from TRPV1^{Cre}-GOF mice infected with IFNAR1-Scr (left) and IFNAR1-shRNA (right) AAVs. Scale bars: 200 pA/20 s. **(G)** Current density evoked by capsaicin in cells represented in G); IFNAR1-Scr (-1.13 ± 0.23 pA/pF, n=41) and IFNAR1-shRNA (-21.56 pA/pF, n=28) neurons. Statistical analysis was performed using the Mann-Whitney test. **** $p < 0.0001$. **(H)** Representative outward potassium currents recorded in TRPV1 neurons from TRPV1^{Cre}-GOF infected with IFNAR1-Scr (left traces) and IFNAR1-shRNA (right traces) AAVs. Scale bars: 1 nA/100 ms. **(I)** Average current-voltage relationship in TRPV1 neurons from TRPV1^{Cre}-GOF mice infected with IFNAR1-Scr (n=31) or IFNAR1-shRNA AAVs (n = 25). Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test. (** $p < 0.01$, **** $p < 0.0001$). Results indicate the mean ± SEM.

Figure 8. KChIP1/Kv4 interaction promotes the antinociceptive effect of ISGs.

(A) Representative current clamp recording of TRPV1 neurons from TRPV1^{cre}-GOF mice, in control condition (left traces) and after AmmTx3 application (right traces). Cells were injected with 500 ms current pulses with an increment of 10 pA and an interval of 5 seconds. Scale bars:

20 mV/50 ms. **(B)** Measurement of the change in Rheobase (left graph) and action potential half-

width (right graph) induced by AmmTx3 application in TRPV1 neurons from TRPV1[cre]-GOF mice

(n=29 neurons). Statistical analysis was performed using a paired t-test. **(C)** Representative

outward potassium currents recorded in TRPV1 neurons from TRPV1[cre]-GOF mice, in control

condition (left traces) and after AmmTx3 application (right traces). Scale bars: 1 nA/100 ms. **(D)**

Current - voltage relationship obtained from the cells recorded in C (n=9). **(E)** Representative

current clamp recording of TRPV1 neurons, from TRPV1[cre]-GOF mice, treated with a TAT-

conjugated KChIP1 peptide for 40 min. Cells were injected with 500 ms current pulses with an

increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. Note that intra-pipette

administration of KChIP1peptide reduces rheobase. **(F)** Time-dependent effect of the TAT-

conjugated KChIP1, but not the denatured control peptide, on the rheobase of TRPV1[Cre]-GOF

neurons (n= 15 and 17, respectively). In contrat, KChIP1 or denatured peptide did not alter the

rheobase of GOF control neurons (n=10 and 11, respectively). **(G)** Measurement of the rheobase

at t=0 and 45 min. post KChIP1 or denatured peptide, in TRPV1 neurons from TRPV1[Cre]-GOF

mice (n=15 for TAT-Denat, n=17 for TAT-KChIP1); or GOF littermate controls (n=10 for TAT-

Denat, n=12 for TAT-KChIP1). Statistical analysis was performed using a paired t-test. **(H)**

Measurement of thermal withdrawal latency in the hind paws of both CFA-treated GOF and

TRPV1[cre]-GOF mice treated with the KChIP1 blocking peptide 5µg (n = 7) or 10µg (n = 6-7); or

its denatured control (n = 6-7), at day three post CFA injection. Statistical analysis was

performed using Two-way ANOVA followed by Tukey post-hoc test (* $p < 0.05$, **** $p <$

0.0001). **(I)** Schematic representation of STING-IFN-I antinociceptive effects in inflammatory

pain models. Activation of nociceptor STING during inflammation stimulates TANK Binding

Kinase 1 (TBK1). TBK1 phosphorylates IFN regulatory factor 3 (IRF3), which controls the

production of Type I IFN, including interferon β (IFNβ). Type I interferons (IFN-I) bind to IFNα/β

receptor (IFNAR) on TRPV1 nociceptors, to initiate the transcriptional regulation of hundreds of

IFN-regulated genes (IRGs), which reduces heat hyperalgesia (TRPV1 downregulation) and

nociceptor excitability (KChIP1 upregulation) and facilitate the return to homeostasis.

Supp Figure 1. **FACS gating strategy to isolate fluorescently labeled neurons from Nav1.8-**

cre Tg/TdTomato and TRPV1-ecGFP mice. **(A)** FACS plots are shown as representative

example of the gating strategy used for Nav1.8-cre Tg/TdTomato lumbar DRG neuron isolation

from contralateral and ipsilateral sides following CFA injection. Lumbar DRG were pooled from
three mice per sample. (**B**) FACS plots are shown as representative example of the gating strategy
used for WT and TRPV1-pHluorin DRG neurons isolation from ipsilateral sides following CFA
injection. Lumbar DRG were pooled from three mice per sample.

Supp Figure 2. **STING deletion enhances nocifensive responses to heat and capsaicin.**
Duration (**A**) and frequency (**B**) of nocifensive behaviors after capsaicin injection in the right hind
paw of WT (n = 13) and STING-/- (n = 19) mice. Statistical analysis was performed using Mann-
Whitney test (*** $p < 0.001$, **** $p < 0.001$). (**C**) Measurement of thermal withdrawal latency in
the hind paws of naïve WT (n = 11) and STING-/-mice (n = 15). Statistical analysis was performed
using Mann-Whitney (*** $p < 0.001$). (**D**) Representative current clamp recording of TRPV1
neurons from WT and STING-/- mice. Cells were injected with 500 ms current pulses with an
increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. (**E**) Measurement of
the rheobase in TRPV1 neurons from WT and STING-/- mice (n = 50 and 58, respectively.
Statistical analysis was performed using an unpaired t-test. (**F**) Number of spikes as a function of
injected current in TRPV1 neurons from WT and STING-/- mice (n = 50 and 58, respectively).
Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test.
(**$p<0.01$, ***$p<0.001$). Results indicate the mean ± SEM.

1012

Supp Figure 3. **Nociceptor-specific hSTING-N154S mutation does not alter the**
neuronanatomical organization of TRPV1 neurons. (**A**) Expression of hSTING and TRPV1 in
DRGs from TRPV1[Cre]-GOF and GOF littermate controls. Scale bars: 50 µm. (**B**) The bar graph
summarizes the percentage of hSTING+ and TRPV1+ neurons normalized to the total number of
neurons. Note that almost ~100% of hSTING+ neurons are TRPV1+ neurons (each symbol
represents a single animal n = 3). Results indicate the mean ± SEM. (**C**) Representative confocal
images of lumbar spinal cord section from TRPV1[Cre]-GOF and GOF littermate controls,
immunostained for Substance P, GFRα3 and GFRα2. Scale bars: 100 µm.

1021

1022 **Supp Figure 4**. **Mice expressing the nociceptor-specific hSTING-N154S mutation exhibit no**
1023 **changes in non-evoked pain-related behaviors and mechanical hyperalgesia.** (**A**) Mechanical
1024 sensitivity in naïve TRPV1[Cre]-GOF and GOF littermate controls (n = 10 and 11, respectively). (**B**)

Measurement of mechanical allodynia in TRPV1^{Cre}-GOF and GOF littermate controls following intraplantar CFA (n = 6 and 8, respectively). **(C-J)** Non-evoked normal behaviors of both naïve GOF (n = 7) and TRPV1^{cre}-GOF (n = 9) mice. Distance **(C)**, Locomotion **(D)**, Immobility **(E)**, Rearing **(F)**, Climbing **(G)**, Drinking **(H)**, Eating **(I)**, Grooming **(J)** behaviors were measured using the Laboras system for 24 hours. Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test. Results indicate the mean ± SEM.

Supp Figure 5. **Nociceptor-specific hSTING-N154S mutation does not induce systemic inflammation.** IFNα **(A)**, IFNβ **(B)**, IL-1β **(C)**, IL-6 **(D)**, TNF-α **(E)** and IL-10 **(F)** levels were determined by Luminex technology in the serum of GOF (n = 4), TRPV1^{cre}-GOF (n = 5), CFA-treated GOF (n = 4) and CFA-treated TRPV1^{cre}-GOF (n = 6) mice. Statistical analysis was performed using Kruskal-Wallis followed by Dunn's post hoc test. Results indicate the mean ± SEM.

Supp Figure 6. Knockdown of IFNAR1 in TRPV1 neurons from TRPV1^{Cre}-GOF mice. (A) Representative confocal image of TRPV1 neurons from TRPV1^{Cre}-GOF mice injected with AAV-DIO-Scr-shRNA (n = 5) or AAV-DIO-IFNAR1-shRNA (n = 5). Images represent DAPI staining, AAV-GFP expression (green) and IFNAR1 transcripts (red) by RNAscope. Scale bars: 25 µm and 10 µm on the cropped images. **(B)** Quantification of IFNAR1 density measured by the number of transcripts represented by dots per surface unit in AAV-infected TRPV1 neurons. Statistical analysis was performed using unpaired t-test (** $p < 0.01$). Results indicate the mean ± SEM.

Supp Figure 7. **Electrophysiological properties of TRPV1-hSTING-N154S expressing neurons. (A)** Measurement of action potential amplitude in TRPV1 neurons from TRPV1^{Cre}-GOF mice and GOF littermate controls. **(B)** Measurement of the resting membrane potential of TRPV1 neurons from TRPV1^{Cre}-GOF mice and GOF littermate controls. **(C)** Measurement of the input resistance of TRPV1 neurons from TRPV1^{Cre}-GOF mice and GOF littermate controls. Results indicate the mean ± SEM (n=61 for GOF and n=101 for TRPV1^{Cre}-GOF). Statistical analysis was performed using unpaired t-test (* $p < 0.05$). Results indicate the mean ± SEM.

Supp Figure 8. **Nociceptor-specific STING-N154S gain of function mutation does not alter**
the excitability of non-peptidergic neurons. (A) Representative current clamp recording of IB4+
neurons from TRPV1[Cre]-GOF mice and GOF littermate controls. Cells were injected with 500 ms
current pulses with an increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms.
(B) Number of spikes as a function of injected current in IB4+ neurons from TRPV1[cre]-GOF mice
and GOF littermate controls. Statistical analysis was performed using a two-way ANOVA test
with Tukey's post-hoc test. Results indicate the mean ± SEM.

1062

Supp Figure 9. **Characterization of peptidergic and non-peptidergic neurons in mice**
expressing the nociceptor-specific hSTING-N154S gain of function mutation. Representative
confocal images of immunostaining for GFRα3 (**A**), Substance P (**C**) and GFRα2 (**E**) in DRGs of
TRPV1[Cre]-GOF and GOF mice. Scale bars: 50 µm. Size distribution of DRG neurons positive for
GFRα3 (**B**), Substance P (**D**) and GFRα2 (**F**) in TRPV1[Cre]-GOF (n = 3) and GOF mice (n = 4).
Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test (**
$p < 0.01$). Results indicate the mean ± SEM.

1070

1071

1072 **Table S1.** Cytokine profiling was determined by Luminex technology in the serum of GOF (n =
1073 4), TRPV1[cre]-GOF (n = 5), CFA-treated GOF (n = 4) and CFA-treated TRPV1[cre]-GOF (n = 6)
1074 mice. Statistical analysis was performed using Kruskal-Wallis followed by Dunn's post hoc test.
1075 Results indicate the mean ± SEM.

1076

Cytokine	GOF Control (pg/ml ± SEM)	GOF CFA (pg/ml ± SEM)	TRPV1[cre]-GOF Control (pg/ml ± SEM)	TRPV1[cre]-GOF CFA (pg/ml ± SEM)	P value
GM-CSF	34.70 ± 3.228	26.16 ± 1.229	32.96 ± 2.764	28.81 ± 2.745	0.1114
IL-2	20.78 ± 4.683	11.17 ± 1.127	10.19 ± 1.093	13.04 ± 1.072	0.0596.
IL-4	4.415 ± 1.244	1.500 ± 0.4823	3.448 ± 1.815	1.457 ± 0.2974	0.1088
IL-12	95.55 ± 20.62	39.28 ± 6.904	239.6 ± 172.8	43.86 ± 6.527	0.1292
MCP-1	334.3 ± 190	136.3 ± 15.44	322.2 ± 115.6	121.1 ± 11.25	0.2296
IFN-y	N.D.	N.D.	N.D.	N.D.	N.D.

1077

References as a guideline, we typically recommend up to 50.

1. Chapman, C. R. & Vierck, C. J. The Transition of Acute Postoperative Pain to Chronic Pain: An Integrative Overview of Research on Mechanisms. *J. pain* **18**, 359.e1-359.e38 (2017).

2. Mifflin, K. A. & Kerr, B. J. The transition from acute to chronic pain: understanding how different biological systems interact. *Can. J. Anaesth.* **61**, 112–122 (2014).

3. Parisien, M. *et al.* Acute inflammatory response via neutrophil activation protects against the development of chronic pain. *Sci. Transl. Med.* **14**, 1–12 (2022).

4. Ji, R. R., Chamessian, A. & Zhang, Y. Q. Pain regulation by non-neuronal cells and inflammation. *Science* **354**, 572–577 (2016).

5. Callaway, E. Scientists deliberately gave people COVID - here's what they learnt. *Nature* **602**, 191–192 (2022).

6. Yang, N. J. *et al.* Anthrax toxins regulate pain signaling and can deliver molecular cargoes into ANTXR2 + DRG sensory neurons. *Nat. Neurosci.* **25**, (2022).

7. Pinho-Ribeiro, F. A. *et al.* Blocking Neuronal Signaling to Immune Cells Treats Streptococcal Invasive Infection. *Cell* **173**, 1083-1097.e22 (2018).

8. Donnelly, C. R., Chen, O. & Ji, R. R. How Do Sensory Neurons Sense Danger Signals? *Trends Neurosci.* **43**, 822–838 (2020).

9. Ishikawa, H. & Barber, G. N. STING an Endoplasmic Reticulum Adaptor that Facilitates Innate Immune Signaling. *Nature* **455**, 674 (2008).

10. Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-Stimulated Genes: A Complex Web of Host Defenses. *Annu. Rev. Immunol.* **32**, 513 (2014).

11. Donnelly, C. R. *et al.* STING controls nociception via type I interferon signalling in sensory neurons. *Nature* **591**, 275–280 (2021).

12. Wang, K. *et al.* STING suppresses bone cancer pain via immune and neuronal modulation. *Nat. Commun.* 1–21 doi:10.1038/s41467-021-24867-2.

13. Sun, C., Wu, G., Zhang, Z., Cao, R. & Cui, S. Protein Tyrosine Phosphatase Receptor Type D Regulates Neuropathic Pain After Nerve Injury via the STING-IFN-I Pathway. *Front. Mol. Neurosci.* **15**, 1–13 (2022).

14. Barragán-iglesias, P. *et al.* Type I Interferons Act Directly on Nociceptors to Produce Pain Sensitization : Implications for Viral Infection-Induced Pain. **40**, 3517–3532 (2020).

15. Wu, W. *et al.* Neuropharmacology Pharmacological inhibition of the cGAS-STING

signaling pathway suppresses microglial M1-polarization in the spinal cord and attenuates
neuropathic pain. *Neuropharmacology* **217**, 109206 (2022).

16.   von Hehn, C. A., Baron, R. & Woolf, C. J. Deconstructing the Neuropathic Pain Phenotype
to Reveal Neural Mechanisms. *Neuron* **73**, 638 (2012).

17.   Basbaum, A. I., Bautista, D. M., Scherrer, G. & Julius, D. Cellular and Molecular
Mechanisms of Pain. *Cell* vol. 139 267–284 (2009).

18.   Agarwal, N., Offermanns, S. & Kuner, R. Conditional gene deletion in primary nociceptive
neurons of trigeminal ganglia and dorsal root ganglia. *Genesis* **38**, 122–129 (2004).

19.   Bourinet, E. *et al.* Calcium-permeable ion channels in pain signaling. *Physiol. Rev.* **94**, 81–
140 (2014).

20.   Defaye, M. *et al.* The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent
pain. *J. Clin. Invest.* **132**, (2022).

21.   Zeisel, A. *et al.* Molecular Architecture of the Mouse Nervous System. *Cell* **174**, 999-
1014.e22 (2018).

22.   Jeltema, D., Abbott, K. & Yan, N. STING trafficking as a new dimension of immune
signaling. *J. Exp. Med.* **220**, 1–14 (2023).

23.   Avraham, O. *et al.* Profiling sensory neuron microenvironment after peripheral and central
axon injury reveals key pathways for neural repair. *Elife* **10**, (2021).

24.   Liu, Y. *et al.* Activated STING in a Vascular and Pulmonary Syndrome. *N. Engl. J. Med.*
371, 507–518 (2014).

25.   Zemel, B. M., Ritter, D. M., Covarrubias, M. & Muqeem, T. A-Type KV Channels in Dorsal
Root Ganglion Neurons: Diversity, Function, and Dysfunction. *Front. Mol. Neurosci.* **11**,
(2018).

26.   Frank An, W. *et al.* Modulation of A-type potassium channels by a family of calcium
sensors. *Nature* **403**, 553–556 (2000).

27.   Olson, G. S. *et al.* Type I interferon decreases macrophage energy metabolism during
mycobacterial infection. *Cell Rep.* **35**, 109195 (2021).

28.   Benmerzoug, S. *et al.* Sterile Lung Inflammation Induced by Silica Exacerbates
Mycobacterium tuberculosis Infection via STING-Dependent Type 2 Immunity. *Cell Rep.*
27, 2649-2664.e5 (2019).

29.   Billiau, A. & Matthys, P. Modes of action of Freund's adjuvants in experimental models of

autoimmune diseases. *J. Leukoc. Biol* **70**, 849–860 (2001).

30.   Zhang, L. *et al.* Article NF- k B activation enhances STING signaling by altering
1142   microtubule-mediated STING trafficking ll NF- k B activation enhances STING signaling
1143   by altering microtubule-mediated STING trafficking. *CellReports* **42**, 112185 (2023).

1144   31.   Riley, J. S., Tait, S. W. G., Riley, J. S. & Tait, S. W. G. Mitochondrial DNA in inflammation
1145   and immunity. 1–17 (2020) doi:10.15252/embr.201949799.

1146   32.   Aarreberg, L. D. *et al.* HHS Public Access. **74**, 801–815 (2019).

1147   33.   Liu, Y., Kuai, S., Ding, M., Wang, Z. & Zhao, L. Dexmedetomidine and Ketamine
1148   Attenuated Neuropathic Pain Related Behaviors via STING Pathway to Induce ER-Phagy.
1149   **14**, 1–12 (2022).

1150   34.   Cavanaugh, D. J. *et al.* Distinct subsets of unmyelinated primary sensory fibers mediate
1151   behavioral responses to noxious thermal and mechanical stimuli. **106**, (2009).

1152   35.   Mishra, S. K., Tisel, S. M., Orestes, P., Bhangoo, S. K. & Hoon, M. A. TRPV1-lineage
1153   neurons are required for thermal sensation. *EMBO J.* **30**, 582–593 (2010).

1154   36.   Saloman, J. L. *et al.* Gi-DREADD expression in peripheral nerves produces ligand-
1155   dependent analgesia, as well as ligand-independent functional changes in sensory neurons.
1156   *J. Neurosci.* **36**, 10769–10781 (2016).

1157   37.   Yu, H. *et al.* Single-Soma Deep RNA sequencing of Human DRG Neurons Reveals Novel
1158   Molecular and Cellular Mechanisms Underlying Somatosensation. *bioRxiv*
1159   2023.03.17.533207 (2023) doi:10.1101/2023.03.17.533207.

1160   38.   David, C. & Frémond, M. L. Lung Inflammation in STING-Associated Vasculopathy with
1161   Onset in Infancy (SAVI). *Cells* **11**, 1–16 (2022).

1162   39.   Saldanha, R. G. *et al.* A Mutation Outside the Dimerization Domain Causing Atypical
1163   STING-Associated Vasculopathy With Onset in Infancy. *Front. Immunol.* **9**, 1535 (2018).

1164   40.   Swann, J. B. *et al.* Type I IFN Contributes to NK Cell Homeostasis, Activation, and
1165   Antitumor Function. *J. Immunol.* **178**, 7540–7549 (2007).

1166   41.   Marcus, A. *et al.* Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response
1167   in Non-tumor Cells to Activate the NK Cell Response. *Immunity* **49**, 754-763.e4 (2018).

1168   42.   Simmons, D. P. *et al.* Type I IFN drives a distinctive dendritic cell maturation phenotype
1169   that allows continued class II MHC synthesis and antigen processing. *J. Immunol.* **188**,
1170   3116–3126 (2012).

43. Kuka, M., De Giovanni, M. & Iannacone, M. The role of type I interferons in CD4+ T cell differentiation. *Immunol. Lett.* **215**, 19–23 (2019).

44. Kolumam, G. A., Thomas, S., Thompson, L. J., Sprent, J. & Murali-Krishna, K. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. *J. Exp. Med.* **202**, 637–650 (2005).

45. Hashimoto, H. *et al.* Type I IFN gene delivery suppresses regulatory T cells within tumors. *Cancer Gene Ther.* **21**, 532–541 (2014).

46. Bacher, N. *et al.* Interferon-α suppresses cAMP to disarm human regulatory T cells. *Cancer Res.* **73**, 5647–5656 (2013).

47. Anz, D. *et al.* Suppression of intratumoral CCL22 by type i interferon inhibits migration of regulatory T cells and blocks cancer progression. *Cancer Res.* **75**, 4483–4493 (2015).

48. Liu, C. C. *et al.* Interferon alpha inhibits spinal cord synaptic and nociceptive transmission via neuronal-glial interactions. *Sci. Rep.* **6**, 1–12 (2016).

49. Ji, R. R., Nackley, A., Huh, Y., Terrando, N. & Maixner, W. *Neuroinflammation and central sensitization in chronic and widespread pain*. *Anesthesiology* vol. 129 (2018).

50. Badimon, A. *et al.* Negative feedback control of neuronal activity by microglia. *Nature* (2020) doi:10.1038/s41586-020-2777-8.

51. Khorooshi, R. & Owens, T. Injury-Induced Type I IFN Signaling Regulates Inflammatory Responses in the Central Nervous System. *J. Immunol.* **185**, 1258–1264 (2010).

52. Rothhammer, V. *et al.* Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. *Nat. Med.* **22**, 586–597 (2016).

53. Ron, D. Translational control in the endoplasmic reticulum stress response. *J. Clin. Invest.* **110**, 1383–1388 (2002).

54. Khoutorsky, A., Sorge, R. E., Prager-khoutorsky, M. & Anne, S. eIF2 α phosphorylation controls thermal nociception. **113**, 11949–11954 (2016).

55. LaCroix-Fralish, M. L., Ledoux, J. B. & Mogil, J. S. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. *Pain* **131**, 3.e1-3.e4 (2007).

56. Neely, G. G. *et al.* A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. *Cell* **143**, 628–638 (2010).

57. Isensee, J. *et al.* Subgroup-elimination transcriptomics identifies signaling proteins that define subclasses of TRPV1-positive neurons and a novel paracrine circuit. *PLoS One* **9**, (2014).

58. Cheng, C. F. *et al.* Coexpression of auxiliary subunits KChIP and DPPL in potassium channel Kv4-positive nociceptors and pain-modulating spinal interneurons. *J. Comp. Neurol.* **524**, 846–873 (2016).

59. Wang, H. *et al.* Structural basis for modulation of Kv4 K+ channels by auxiliary KChIP subunits. *Nat. Neurosci.* **10**, 32–39 (2007).

60. Pioletti, M., Findeisen, F., Hura, G. L. & Minor, D. L. Three-dimensional structure of the KChIP1-Kv4.3 T1 complex reveals a cross-shaped octamer. *Nat. Struct. Mol. Biol.* **13**, 987–995 (2006).

61. Jerng, H. H., Pfaffinger, P. J. & Covarrubias, M. Molecular physiology and modulation of somatodendritic A-type potassium channels. *Mol. Cell. Neurosci.* **27**, 343–369 (2004).

62. Kuo, Y. L. *et al.* K + channel modulatory subunits KChIP and DPP participate in Kv4-mediated mechanical pain control. *J. Neurosci.* **37**, 4391–4404 (2017).

63. Cui, Y. Y., Liang, P. & Wang, K. W. Enhanced trafficking of tetrameric Kv4.3 channels by KChIP1 clamping. *Neurochem. Res.* **33**, 2078–2084 (2008).

64. Na Phuket, T. R. & Covarrubias, M. Kv4 Channels Underlie the Subthreshold-Operating A-type K-current in Nociceptive Dorsal Root Ganglion Neurons. *Front. Mol. Neurosci.* **2**, (2009).

65. Matsuyoshi, H. *et al.* Distinct cellular distributions of Kv4 pore-forming and auxiliary subunits in rat dorsal root ganglion neurons. *Life Sci.* **91**, 258–263 (2012).

66. Yunoki, T. *et al.* Differential contribution of Kv4-containing channels to A-type, voltage-gated potassium currents in somatic and visceral dorsal root ganglion neurons. *J. Neurophysiol.* **112**, 2492–2504 (2014).

67. Chien, L. Y., Cheng, J. K., Chu, D., Cheng, C. F. & Tsaur, M. L. Reduced expression of A-type potassium channels in primary sensory neurons induces mechanical hypersensitivity. *J. Neurosci.* **27**, 9855–9865 (2007).

68. Duan, K. Z. *et al.* Targeting A-type K(+) channels in primary sensory neurons for bone cancer pain in a rat model. *Pain* **153**, 562–574 (2012).

69. Trimmer, J. S. Subcellular localization of K+ channels in mammalian brain neurons:

Remarkable precision in the midst of extraordinary complexity. *Neuron* **85**, 238–256
(2015).

70. Zheng, Y. *et al.* Deep Sequencing of Somatosensory Neurons Reveals Molecular
Determinants of Intrinsic Physiological Properties. *Neuron* **103**, 598-616.e7 (2019).

71. Yang, F. & Zheng, J. High temperature sensitivity is intrinsic to voltage-gated potassium
channels. *Elife* **3**, e03255 (2014).

72. Diogenes, A., Ferraz, C. C. R., Akopian, A. N., Henry, M. A. & Hargreaves, K. M. LPS
sensitizes TRPV1 via activation of TLR4 in trigeminal sensory neurons. *J. Dent. Res.* **90**,
759–764 (2011).

73. Donnelly, C. R. *et al. STING controls nociception via type I interferon signalling in sensory*
neurons. *Nature* vol. 591 (Springer US, 2021).

74. Bruno, K. *et al.* Targeting toll-like receptor-4 (TLR4)-an emerging therapeutic target for
persistent pain states. *Pain* **159**, 1908–1915 (2018).

75. Min, H. *et al.* Association of TRPV1 and TLR4 through the TIR domain potentiates TRPV1
activity by blocking activation-induced desensitization. *Mol. Pain* **14**, (2018).

76. Dixon, W. J. Efficient analysis of experimental observations. *Annu. Rev. Pharmacol.*
Toxicol. **20**, 441–462 (1980).

77. Chaplan, S. R., Bach, F. W., Pogrel, J. W., Chung, J. M. & Yaksh, T. L. Quantitative
assessment of tactile allodynia in the rat paw. *J. Neurosci. Methods* **53**, 55–63 (1994).

78. Quinn, L. P. *et al.* LABORAS[TM]: Initial pharmacological validation of a system allowing
continuous monitoring of laboratory rodent behaviour. *J. Neurosci. Methods* **130**, 83–92
(2003).

79. Dobin, A. *et al.* STAR: ultrafast universal RNA-seq aligner. *Bioinformatics* **29**, 15–21
(2013).

80. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**, 2078–
2079 (2009).

81. Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work with high-
throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).

82. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion
for RNA-seq data with DESeq2. *Genome Biol.* **15**, (2014).

1263

Figure 1. Transcriptional changes in Nav1.8 and TRPV1 neurons after CFA inflammation. (A) Experimental approach used to isolate Nav1.8Tg-TdTomato neurons for microarray analysis, 24 hours after intraplantar CFA. **(B)** Volcano plot showing transcriptional changes induced by CFA inflammation in Nav1.8Tg-TdT neurons (n = 3 mice). P-value line cut-off is p<0.01, and fold change of 2. Select transcripts of interest are highlighted in distinct colors (legend). **(C)** Experimental approach used to isolate TRPV1-ecGFP neurons for microarray analysis, 72 hours after intraplantar CFA. **(D)** Volcano plot showing transcriptional changes induced by CFA inflammation in TRPV1 neurons. P-value line cut-off is p<0.05, and fold change of 1.5. Select transcript of interest is highlighted in red (legend). **(E)** Representative confocal images of co-immunostaining for STING and TRPV1-ecGFP in both ipsilateral and contralateral DRG neurons of CFA-treated mice. Scale bars: 50 µm. **(F)** Dot plot showing the percentage of neurons co-expressing STING and TRPV1 in DRG from TRPV1-ecGFP mice (from n = 3 mice). Statistical analysis was performed using Kruskal-Wallis followed by Dunn's post-hoc test (** p < 0.01, *** p < 0.001). Results indicate the mean ± SEM.

Figure 2. STING is expressed in mouse and human DRG nociceptors. (A) Heatmap of the expression of STING and selected population markers on the 15 populations of sensory neurons from DRG described in Zeisel et al., [21]. (**B**) Representative confocal images of co-immunostaining for STING and IB4, GFRα2, TRPV1 and GFRα3 in mouse DRG neurons. Scale bars: 50 µm. (**C**) Dot plot showing the percentage of peptidergic (TRPV1, GFRα3) and non-peptidergic (IB4, GFRα2) neurons co-expressing STING in DRG from TRPV1-ecGFP mice (n = 3 mice). Statistical analysis was performed using Kruskal-Wallis followed by Dunn's post-hoc test (** p < 0.01, *** p < 0.001, **** p<0.001). (**D**) Representative RNAscope image showing expression of STING (light blue) in human DRG neurons co-expressing Nav1.8 (pink). (**E**) The bar graph summarizes the results (each symbol represents a single DRG; n = 3 for one patient and n = 4 for another patient). The results are presented as the mean ± SEM.

Figure 3. Activation of STING induces type IFN-I through TBK1 in nociceptors. (**A**) Phospho-TBK1 (p-TBK1) protein level was determined by Western blot in the lumbar DRG neurons culture (L4-L6) treated with Vehicle (n = 3) or ADU-S100 for three hours (n = 3) from WT and STING-/- mice. (**B**) Bar graph representing p-TBK1 quantification. Data are normalized to TBK1 signal. Statistical analysis was performed using One-way ANOVA followed by Tukey post-hoc rest (*** p < 0.001). IFNα (**C**) and IFNβ (**D**) levels were determined by Luminex technology in the DRG culture of WT (n = 4) and STING-/- (n =4-8) DRG cultures treated with Vehicle or ADU-S100. Statistical analysis was performed using One-way ANOVA followed by Tukey post hoc test (**** p < 0.0001). (**E**) IFNβ levels were determined by Luminex technology in Vehicle (n = 4) and RTX (n = 3) pre-treated DRG neurons, stimulated with ADU-S100. Statistical analysis was performed using One-way ANOVA followed by Tukey post hoc test (* p < 0.05; *** p < 0.001; **** p < 0.0001). Results indicate the mean ± SEM.

Figure 4. Nociceptor-specific STING-N154S gain of function reduces thermal sensitivity and heat hyperalgesia in an IFNAR1 dependent manner. (A) Schematic representation of the transgenic TRPV1[cre]-GOF cKi mouse design. (**B**) IFNα levels were determined by Luminex technology in DRG cultures of GOF (n = 4) and TRPV1[cre]-GOF (n = 6) mice and stimulated with ADU-S100. Statistical analysis was performed using Kruskal-Wallis followed by Dunn's post hoc test (* $p < 0.05$). (**C**) IFNβ levels were determined by Luminex technology in DRG cultures of GOF (n = 4) and TRPV1[cre]-GOF (n = 6) mice and stimulated with ADU-S100. Statistical analysis was performed using One-Way ANOVA by Tukey post hoc test (** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$). (**D-E**) Measurement of thermal sensitivity in hind paws of naïve TRPV1[cre]-GOF (n = 15-16) and littermate control GOF mice (n = 7-12) using the Hot plate (**D**) or Hargreaves test (**E**). Statistical analysis was performed using t-test (**D**) or Mann-Whitney test (**E**) (** $p < 0.01$, **** $p < 0.0001$). (**F**) Measurement of edema in the ipsilateral and contralateral hind paws of CFA-treated GOF mice (n = 9) and TRPV1cre-GOF mice (n = 8). Statistical analysis was performed using One-Way ANOVA followed by Tukey post-hoc test (** $p < 0.01$, **** $p < 0.0001$). (**G**) Measurement of thermal withdrawal latency in the ipsilateral and contralateral hind paws of GOF (n = 9) and TRPV1[cre]-GOF (n = 8) mice that were treated with CFA. Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$). (**H**) Measurement of thermal withdrawal latency in the hind paws of CFA-treated TRPV1[cre]-GOF mice that received either an IgG control (n = 5) or IFNAR1 neutralizing antibody (MAR-1) prior to CFA injection and at day three post CFA injection (n = 6). Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). (**I**) Newly born pups (postnatal day 5) were administered 10 µL of AAV-PHP.S-DIO-IFNAR1-shRNA or AAV-PHP.S-DIO-scrambled-shRNA intraperitoneally. (**J**) Measurement of thermal sensitivity in the hind paws of AAV-DIO-scram-shRNA (n = 9) and AAV-DIO-IFNAR1-shRNA (n = 16) injected mice. Statistical analysis was performed using t-test (**** $p < 0.0001$). (**K**) Measurement of thermal withdrawal latency in the ipsilateral and contralateral hind paws of AAV-DIO-scram-shRNA (n = 7) and AAV-DIO-IFNAR1-shRNA (n = 9) infected mice treated with CFA. Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test (** $p < 0.01$, **** $p < 0.0001$ vs AAV-DIO-scram-shRNA i.l.; ($$ $p < 0.01$, $$$$ $p < 0.0001$, vs AAV-DIO-scram-shRNA c.l.). Results indicate the mean ± SEM.

Figure 5. Nociceptor-specific STING-N154S gain of function induces IFN-I production and expression of Interferons Stimulated Genes (ISGs) in DRGs. (**A**) Volcano plot representation of genes regulated in naive TRPV1cre-GOF cKi mice. Genes that pass a threshold of log1.5-fold change in differential expression analysis are colored in green when they are downregulated and red when they are upregulated. (**B**) OASL2 expression in lumbar DRG neurons of naïve GOF (n = 6) and TRPV1cre-GOF (n = 9) mice. Statistical analysis was performed using t-test (**** p < 0.0001). (**C**) ISG15 expression in lumbar DRG neurons of naive GOF (n = 6) and TRPV1cre-GOF (n = 9) mice. Statistical analysis was performed using Mann-Whitney test (*** p < 0.001). (**D**) KChIP1 expression in lumbar DRG neurons of naive GOF (n = 7) and TRPV1cre-GOF (n = 13) mice. Statistical analysis was performed using t-test (**** p < 0.0001). (**E**) TRPV1 expression in lumbar DRG neurons of naive GOF (n = 6) and TRPV1cre-GOF (n = 8) mice. Statistical analysis was performed using t-test (* p < 0.05). Results indicate the mean ± SEM.

Figure 6. **ISGs alter nociceptor properties through TRPV1 downregulation and KChIP1 expression.** (**A**) Representative current clamp recording of evoked action potentials recorded in TRPV1 neurons (TdTomato+) from GOF (left) and TRPV1^{cre}-GOF (right) mice. Cells were injected with a 500 ms current pulse with an increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. (**B**) Rheobase data recorded in TRPV1 (TdTomato+) and non-peptidergic (IB4+) neurons from GOF mice (45.33 ± 4.72 pA, n=61 TRPV1+ neurons; 25.63 ± 5.40 pA, n=16 IB4+ neurons) and TRPV1^{cre}-GOF mice (103.70 ± 6.85 pA, n=101 TRPV1+ neurons; 29.09 ± 2.86 pA, n=22 IB4+ neurons). Statistical analysis was performed using the Kruskal-Wallis test with Dunn's multiple comparison test. **** $p < 0.0001$. (**C**) Number of spikes as a function of injected current in TRPV1 neurons from TRPV1^{cre}-GOF mice and GOF littermate controls. Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test. (** $p < 0.01$, *** $p < 0.001$). (**D**) Representative action potentials recorded in TRPV1 neurons from GOF (black) and TRPV1^{cre}-GOF (red) mice. Scale bars: 20 mV/50 ms. (**E**) Action potential half-width recorded in TRPV1 neurons from GOF (3.86 ± 0.21 ms, n=61) and TRPV1^{cre}-GOF (2.73 ± 0.82 ms, n=101) mice. Statistical analysis was performed using the Mann-Whitney test. **** $p < 0.0001$. (**F**) Representative currents induced by 100 nM of capsaicin in TRPV1 neurons from GOF (left) and TRPV1^{cre}-GOF (right) mice. Scale bars: 200 pA/10 s. (**G**) Current density evoked by capsaicin in TRPV1 neurons from GOF (-21.93 ± 7.51 pA/pF, n=25) and TRPV1^{cre}-GOF (-2.85 ± 0.96 pA/pF, n=70) mice. Statistical analysis was performed using the Mann-Whitney test. ****$p<0.0001$. (**H**) Representative confocal images of TRPV1 immunostaining in lumbar DRG neurons of naïve GOF and TRPV1^{cre}-GOF mice. Scale bars: 50 µm. (**I**) Size distribution of the percentage of DRG neurons immunopositive for TRPV1, in naïve GOF (n = 3) and TRPV1^{cre}-GOF mice (n = 3). Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test (** $p < 0.01$). (**J**) Western blot of KChIP1 and β-tubulin from lumbar DRG lysates. (**K**) Quantification of KChIP1 protein level in DRG lysates from naïve GOF (n = 4) and TRPV1^{cre}-GOF (n = 5) mice, measured by Western blot. Statistical analysis was performed using the Mann-Whitney test (* $p < 0.05$). (**L**) Representative outward potassium currents recorded in TRPV1 neurons from GOF (left traces) and TRPV1^{cre}-GOF (right traces) mice. Scale bars: 1 nA/100 ms. (**M**) Current – Voltage relationship from neurons recorded in (L). GOF (n=10) and TRPV1^{cre}-GOF (n=17). (**N**) Steady-state activation and inactivation (**O**) from neurons recorded in (L). Activation; GOF: V1/2 = 3.567 mV, K=18.68 mV, n=17; TRPV1^{cre}-GOF: V1/2 = -3.779 mV, K=21.20 mV, n=17. Inactivation; GOF: V1/2 = -48.31 mV, K=-8.72 mV, n=18; TRPV1^{cre}-GOF: V1/2 = -41.56 mV, K=-13.01 mV, n=25. All steady-state plots were fitted with Boltzmann functions to derive V1/2 and K values. Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test. (** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$). Results indicate the mean ± SEM.

A

IFNAR1-Scr

IFNAR1-shRNA

DAPI　　GFP　　KChIP1　　Overlap

B

KChIP1 density (Dot/µm²)

IFNAR1-Scr
IFNAR1-shRNA

****

C

IFNAR1-Scr　　IFNAR1-shRNA

X20

Injected current (pA)

D

Rh (pA)

****

IFNAR1-Scr
IFNAR1-shRNA
IFNAR1-Scr (GFP-)
IFNAR1-shRNA (GFP-)

E

Number of spikes

**　　****

IFNAR1-Scr
IFNAR1-shRNA

Injected current (pA)

F

IFNAR1-Scr　　IFNAR1-shRNA

capsaicin

G

Density (pA/pF)

****

IFNAR1-Scr
IFNAR1-shRNA

H

IFNAR1-Scr　　IFNAR1-shRNA

I

Density (pA/pF)

****　****　****　****　****
**

IFNAR1-Scr
IFNAR1-shRNA

Vm (mV)

Figure 7. **IFNAR1 depletion in nociceptors restores electrophysiological properties**. (**A**) Representative confocal image of TRPV1 neurons from TRPV1^{Cre}-GOF mice injected with AAV-DIO-Scr-shRNA (n = 5) or AAV-DIO-IFNAR1-shRNA (n = 5). Images represent DAPI staining, AAV-GFP expression (green) and KChIP1 transcripts (red) by RNAscope. Scale bars: 25 µm and 10 µm on the cropped images. (**B**) Quantification of KChIP1 density measured by the number of transcripts represented by dots per surface unit in AAV-infected TRPV1 neuron. Statistical analysis was performed using unpaired t-test (**** $p < 0.0001$). (**C**) Representative current clamp recording of TdTomato+/GFP+ TRPV1 neurons from TRPV1^{Cre}-GOF mice infected with DIO-Scram-shRNA (left) or DIO-IFNAR1-shRNA (green) AAVs. Cells were injected with 500 ms current pulses with an increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. (**D**) Measurement of Rheobase in infected (GFP+) and non-infected (GFP-) TRPV1 neurons (TdTomato+) recorded in (D). Data are presented as dot plots with mean values (172.8 ± 11.04 pA, n=89 for IFNAR1-Scr neurons; 56.13 ± 2.75 pA, n=80 for IFNAR1-shRNA infected neurons; and 208.30 ± 21.89 pA, n=18 for IFNAR1-Scr neurons; 251.10 ± 24.77 pA, n=18 for IFNAR1-shRNA non-infected neurons). Statistical analysis was performed using the Mann-Whitney test. ****$p<0.0001$. (**E**) Number of spikes evoked by injected current in TRPV1 (TdTomato+) and AAV infected (GFP+) neurons. Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test. (** $p < 0.01$, **** $p <0.0001$). (**F**) Representative capsaicin-evoked current in TdTomato+/GFP+ TRPV1 neurons from TRPV1^{Cre}-GOF mice infected with IFNAR1-Scr (left) and IFNAR1-shRNA (right) AAVs. Scale bars: 200 pA/20 s. (**G**) Current density evoked by capsaicin in cells represented in G); IFNAR1-Scr (-1.13 ± 0.23 pA/pF, n=41) and IFNAR1-shRNA (-21.56 pA/pF, n=28) neurons. Statistical analysis was performed using the Mann-Whitney test. **** $p < 0.0001$. (**H**) Representative outward potassium currents recorded in TRPV1 neurons from TRPV1^{Cre}-GOF infected with IFNAR1-Scr (left traces) and IFNAR1-shRNA (right traces) AAVs. Scale bars: 1 nA/100 ms. (**I**) Average current-voltage relationship in TRPV1 neurons from TRPV1^{Cre}-GOF mice infected with IFNAR1-Scr (n=31) or IFNAR1-shRNA AAVs (n = 25). Statistical analysis was performed using a two-way ANOVA test with Tukey's post-hoc test. (** $p < 0.01$, **** $p < 0.0001$). Results indicate the mean ± SEM.

Figure 8. KChIP1/Kv4 interaction promotes the antinociceptive effect of ISGs.

(A) Representative current clamp recording of TRPV1 neurons from TRPV1[cre]-GOF mice, in control condition (left traces) and after AmmTx3 application (right traces). Cells were injected with 500 ms current pulses with an increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. **(B)** Measurement of the change in Rheobase (left graph) and action potential half-width (right graph) induced by AmmTx3 application in TRPV1 neurons from TRPV1[cre]-GOF mice (n=29 neurons). Statistical analysis was performed using a paired t-test. **(C)** Representative outward potassium currents recorded in TRPV1 neurons from TRPV1[cre]-GOF mice, in control condition (left traces) and after AmmTx3 application (right traces). Scale bars: 1 nA/100 ms. **(D)** Current - voltage relationship obtained from the cells recorded in C (n=9). **(E)** Representative current clamp recording of TRPV1 neurons, from TRPV1[cre]-GOF mice, treated with a TAT-conjugated KChIP1 peptide for 40 min. Cells were injected with 500 ms current pulses with an increment of 10 pA and an interval of 5 seconds. Scale bars: 20 mV/50 ms. Note that intra-pipette administration of KChIP1peptide reduces rheobase. **(F)** Time-dependent effect of the TAT-conjugated KChIP1, but not the denatured control peptide, on the rheobase of TRPV1[Cre]-GOF neurons (n= 15 and 17, respectively). In contrat, KChIP1 or denatured peptide did not alter the rheobase of GOF control neurons (n=10 and 11, respectively). **(G)** Measurement of the rheobase at t=0 and 45 min. post KChIP1 or denatured peptide, in TRPV1 neurons from TRPV1[Cre]-GOF mice (n=15 for TAT-Denat, n=17 for TAT-KChIP1); or GOF littermate controls (n=10 for TAT-Denat, n=12 for TAT-KChIP1). Statistical analysis was performed using a paired t-test. **(H)** Measurement of thermal withdrawal latency in the hind paws of both CFA-treated GOF and TRPV1[cre]-GOF mice treated with the KChIP1 blocking peptide 5µg (n = 7) or 10µg (n = 6-7); or its denatured control (n = 6-7), at day three post CFA injection. Statistical analysis was performed using Two-way ANOVA followed by Tukey post-hoc test (* $p < 0.05$, **** $p < 0.0001$). **(I)** Schematic representation of STING-IFN-I antinociceptive effects in inflammatory pain models. Activation of nociceptor STING during inflammation stimulates TANK Binding Kinase 1 (TBK1). TBK1 phosphorylates IFN regulatory factor 3 (IRF3), which controls the production of Type I IFN, including interferon β (IFNβ). Type I interferons (IFN-I) bind to IFNα/β receptor (IFNAR) on TRPV1 nociceptors, to initiate the transcriptional regulation of hundreds of IFN-regulated genes (IRGs), which reduces heat hyperalgesia (TRPV1 downregulation) and nociceptor excitability (KChIP1 upregulation) and facilitate the return to homeostasis.

A

c.l.

Nav1.8Tg-TdTomato

4.17%

Side Scatter

i.l.

4.49%

B

Forward Scatter

WT

TRPV1-pHluorin

GFP

SUPP FIGURE 1: Gating Strategies for FACS

A

GOF

TRPV1^cre^-GOF

DAPI   TRPV1   hSTING   Overlap

B

% of neurons

hSTING+   TRPV1+   hSTING+TRPV1+

C

<u>Spinal cord</u>

GOF   TRPV1^cre^-GOF

tdTomato
Substance P
Merge

GOF   TRPV1^cre^-GOF

tdTomato
GFRα3
Merge

GOF   TRPV1^cre^-GOF

tdTomato
GFRα2
Merge

SUPP FIGURE 3: STING-N154S expression does not alter the neuronanatomical organization of TRPV1+ neurons

SUPP FIGURE 4: STING-N154S expression does not alter mechanical allodynia and locomotor function

SUPP FIGURE 5: STING-N154S expression does not induce systemic inflammation

A

B

IFNAR1 density (Dot/μm^2)

**

SUPP FIGURE 6: Electrophysiological properties of the TRPV1-hSTING-N154S expressing neurons

A

GOF_IB4+ TRPV1^cre-GOF_IB4+

B

SUPP FIGURE 8: STING-N154S expression does not alter the excitability of non-peptidergic neurons

SUPP FIGURE 9: STING-N154S expression does not alter the proportion of peptidergic and non peptidergic neurons

Cytokine	GOF Control (pg/ml ± SEM)	GOF CFA (pg/ml ± SEM)	TRPV1[cre]-GOF Control (pg/ml ± SEM)	TRPV1[cre]-GOF CFA (pg/ml ± SEM)	P value
GM-CSF	34.70 ± 3.228	26.16 ± 1.229	32.96 ± 2.764	28.81 ± 2.745	0.1114
IL-2	20.78 ± 4.683	11.17 ± 1.127	10.19 ± 1.093	13.04 ± 1.072	0.0596.
IL-4	4.415 ± 1.244	1.500 ± 0.4823	3.448 ± 1.815	1.457 ± 0.2974	0.1088
IL-12	95.55 ± 20.62	39.28 ± 6.904	239.6 ± 172.8	43.86 ± 6.527	0.1292
MCP-1	334.3 ± 190	136.3 ± 15.44	322.2 ± 115.6	121.1 ± 11.25	0.2296
IFN-y	N.D.	N.D.	N.D.	N.D.	N.D.

Table 1: list of cytokines